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Metastasis is a major contributor to breast cancer mortality, as currently available therapies are 
unable to ensure progression or disease-free survival. Little is known about the molecular 
pathogenesis of metastasis, and the role of the surrounding microenvironment is only beginning to 
be understood. In vitro studies have repeatedly shown that epithelial to mesenchymal transition 
(EMT) and loss of E-cadherin expression are critical events in the initiation of metastasis and can 
be induced by the microenvironment. However, metastases are often well-differentiated and 
epithelial in phenotype, suggesting that EMT is reversible. The role of E-cadherin expression and 
mesenchymal to epithelial reverting transition (MErT) in metastatic colonization of the secondary 
site remains ill-defined. Evidence for E-cadherin re-expression and partial MErT was observed in 
metastases of breast and prostate cancer patients, and suggests that MErT is unstable and 
reversible. MDA-MB-231 breast cancer cells cultured with hepatocytes also resulted in E-
cadherin re-expression and partial MErT, suggesting that such phenotypic plasticity can be 
induced by the microenvironment of the liver, a key site of breast cancer metastases. Re-
expression of E-cadherin following hepatocyte coculture not only results in heterotypic ligation 
between cancer and liver parenchymal cells, but also activates Erk survival signaling and 
increases resistance to nutrient-deprivation and chemotherapy. Taken together, our results indicate 
that the distant organ microenvironment may induce E-cadherin re-expression and partial MErT 
to enhance the survival of metastatic cancer cells at the secondary organ.  
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1.0  INTRODUCTION 
Breast cancer is a significant clinical problem that will afflict 1 in 8 women in her lifetime. Even 
with increased earlier detection and utilization of targeted therapies such as tamoxifen and 
Herceptin, the rates of patients diagnosed with metastatic breast cancer has not changed.  
Metastasis is still the major cause of breast cancer mortality, with no currently available 
therapies capable of ensuring disease-free, or even progression-free survival. Throughout 
metastasis, the cancer cell exhibits remarkable plasticity during its trek from primary site to 
distant organ, enabling it to survive through drastically different microenvironments. While 
previously this plasticity had been attributed to intrinsic genetic instability enabling in vivo 
selection of adaptability, current understanding is that the tumor behaves like a complex organ. 
Whether it is through interactions with immune and stromal cells or with the extracellular matrix, 
cancer cells are constantly engaging with the microenvironment, which greatly contributes to the 
plasticity of cancer cells. Also critical to the idea of phenotypic plasticity is that the metastatic 
cancer cell is a moving target, both literally and figuratively, and that therapies that work to 
prevent invasion in the primary tumor may have a different effect on already disseminated cells. 
Thus, elucidating the role of the microenvironment on cancer cell plasticity may significantly 
affect the way new therapeutics are developed, as targeting the microenvironment in tandem may 
lead to greater therapeutic success. 
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1.1 BREAST CANCER 
Approximately 200,000 women are diagnosed with breast cancer each year, making breast 
cancer the most common malignancy that strikes women in the United States and the second 
leading cause of cancer-related deaths. Women born today have a lifetime-risk of 12.5% of 
developing breast cancer later in life (Altekruse et al., 2010). Male breast cancer accounts for 
only 1% of all cases, with 2,000 new diagnoses each year. While increased screening has 
improved detection of breast cancer at earlier stages, mortality rates have not decreased because 
the number of women who develop advanced or metastatic disease has stayed the same.  
1.1.1 Breast Anatomy 
Breast carcinoma is a disease of the epithelia of the mammary gland, the presence of which 
defines the biological class of mammals. In humans, each breast comprises 5 to 9 mammary 
glands. Each mammary gland, also known as a ductal system, is composed of milk-secreting 
alveoli that cluster to form lobules that drain milk into ducts leading to the nipple (Love and 
Barsky, 2004). On a cellular level, alveoli are lined with cuboidal cells that produce and secrete 
milk. Ducts are composed of a bilayer of luminal epithelial cells and basal, or myoepithelial, 
cells that sit on a basement membrane. Mammary stroma consisting of extracellular matrix 
(ECM), fibroblasts, adipocytes, and inflammatory cells surrounds the ductal systems 
(Kuperwasser et al., 2004; Egeblad et al., 2010).  
Starting in puberty, each simple mammary gland begins elaborate branching that results 
in a tree of multiple ducts and lobules. During menstruation and pregnancy there are additional 
cycles of cell proliferation and budding. Thus stem cells are necessary to replenish the ductal and 
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lobular cells at these times. Based on expression of cell surface markers, studies have uncovered 
distinct cell populations in the breast: a mammary stem cell (MSC) population gives rise to basal 
and luminal progenitors and mature luminal and basal populations. Mammary stem cells are 
basally located in ducts and surrounded by proliferating progenitor cells. MSCs are believed to 
represent about 1:2000 of mammary epithelial cells (Stingl et al., 2001; Villadsen et al., 2007; 
Lim et al., 2009).  
1.1.2 Classification 
Breast cancer patients are clinically stratified according to stage, histopathology, and hormone 
receptor/marker expression to determine prognosis, risk of recurrence, and course of treatment. 
Tumors are staged according to the tumor node metastasis (TNM) system, which is based on 
tumor size and spread to adjacent lymph nodes or distant organs. Breast carcinomas can be 
categorized histopathologically into 18 subtypes with infiltrating ductal (IDC) and invasive 
lobular (ILC) being the most common at 75 and 15 percent of cases, respectively (Li et al., 2005; 
Harris et al., 2009). Breast cancers can also be classified according to expression of estrogen 
(ER) and progesterone receptors (PR) and amplification of the oncogene HER2/Neu.  
While use of the criteria described above has been able to provide prognostic value, 
response to therapy within groups is still very heterogeneous. As a result, efforts are being made 
to discover molecular profiles or biomarkers to more accurately predict outcome. Recently, 
differences in gene expression patterns have resulted in the introduction of 6 molecular subtypes: 
Luminal A, Luminal B, HER2-enriched, Basal-like, Claudin-low and Normal Breast-like. 
Luminal A tumors are characterized by high ER/PR expression, low HER2 expression, and low 
expression of markers of proliferation. Luminal B tumors have weaker ER/PR expression 
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compared to Luminal A tumors, variable HER2 expression, and high expression of proliferation 
markers. Tumors of the HER2-enriched subtype are marked by high HER2 amplification with 
absent expression of ER/PR while the Basal-like subtype typically consists of tumors negative 
for ER/PR and HER2 (commonly called triple negative). The Claudin-low subtype was 
previously considered a sub-population of the Basal-like subtype and includes triple negative 
tumors that exhibit low expression of cell adhesion molecules, high expression of mesenchymal 
and stem cell markers, and lower expression of proliferation markers (Perou et al., 2000; Sorlie 
et al., 2001; Herschkowitz et al., 2007; Prat et al., 2010). While these molecular subtypes are not 
currently used to affect treatment, they have been shown to correlate with prognosis, with 
Luminal A and B carrying the best and Basal-like carrying the worst prognosis (O'Brien et al., 
2010).  
It has been hypothesized that the molecular subtypes originate from different cell types 
(Prat and Perou). Women with BRCA-1 mutations are more likely to develop Basal-like tumors, 
and recent evidence suggests that they result from transformation of a luminal progenitor 
population. In addition, gene expression of the MSC population most closely aligns with the 
Claudin-low subtype while the mature luminal signature is closest to the Luminal A and B 
subtypes (Lim et al., 2009). Importantly, while the majority of cases can be segregated into the 
molecular subtypes according to expression of ER/PR/HER2, this is not always the case. For 
example, not all Basal-like tumors are triple negative and vice versa (Prat and Perou, 2010).  
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1.1.3 Tumorigenesis 
About 5-10% of breast cancer cases are hereditary, or the result of familial genetic mutations 
BRCA1 and BRCA2. The incidence of breast cancers that are attributed to genetic mutations 
increases in younger patient cohorts, with about 36% of patients diagnosed with breast cancer 
between the ages of 20 to 29 exhibiting mutations. Mutations in BRCA, a gene involved in the 
cell response to DNA damage, are autosomal dominant with varied penetrance. Thus reports of 
the lifetime risk of cancer of patients with BRCA mutations range from 36% to as high as 97% 
lifetime risk (Harris et al., 2009). 
Besides the small percentage of cases that exhibit hereditary genetic mutations, breast 
cancer is for the most part a remarkably heterogeneous disease as there are few genetic insults 
that are common among all cases, unlike some other carcinomas.  Tumorigenesis is a multi-step 
process that results from several genetic alterations that affect basic cell physiology resulting in 
malignant growth. Alterations that affect active growth signals, evasion of apoptosis, resistance 
to anti-growth signals, limitless replication, sustained angiogenesis, and tissue invasion can all 
contribute to tumorigenesis (Hanahan and Weinberg, 2000). Adding to the complexity, genetic 
insults do not even necessarily have to occur in the same cell. In Drosophila, tumor formation 
can result from different mutations in two adjacent epithelial cells (Wu et al., 2010). It has been 
proposed from pathologic observation that tumor transformation and progression is linear, with 
epithelial atypia, hyperplasia, and carcinoma in situ (DCIS or LCIS) as precursors to the invasive 
ductal and lobular carcinomas that are most common in breast cancer patients (Bombonati and 
Sgroi, 2011). However, genetic studies comparing chromosomal abnormalities in DCIS and IDC 
suggest that linear progression may not necessarily be the case (Buerger et al., 1999). 
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There is much debate about the cancer cell of origin. The clonal model posits that any 
epithelial cell is capable of garnering the mutations needed to initiate a tumor. The cancer stem 
hypothesis argues that only a small population of cells is capable of initiating a tumor – either 
tissue stem or progenitor cells or cells that have acquired mutations leading to stem-like abilities. 
Because stem cells are long-lived and have the capacity for self-renewal and asymmetric 
division, they are more likely to acquire the genetic alterations for transformation, maintain the 
stem cell population and generate the heterogeneous tumor (Al-Hajj et al., 2003). Although 
transformed stem or progenitor cells are well-established in hematopoietic malignancies, the 
existence of a breast cancer stem cell is still controversial as tumor-initiating capacity depends 
widely on the experimental model used (Kelly et al., 2007; Quintana et al., 2008; Rosen and 
Jordan, 2009). 
1.1.4 Primary tumor microenvironment 
Despite the fact that a “carcinoma” indicates that the cancer is derived from an epithelial cell, 
tumors are like complex ecosystems in that they consist of many other cell types besides 
epithelial cells. The mammary gland derives from the ectoderm, but responds to underlying 
mesenchyme to form a breast bud (Anbazhagan et al., 1998). Even in adults the breast remains 
very responsive to signals from mesenchymal cells and embryonic mammary mesenchyme can 
induce differentiation in breast cancer explants (DeCosse et al., 1973). Thus, the mammary 
stroma is a significant part of the breast cancer tumorigenesis and participates in bi-directional 
interactions with epithelial cells. Interactions with recruited immune cells and endothelial cells 
can also affect tumorigenesis as failed immune surveillance of transformed cells results in frank 
tumor growth (Tlsty and Coussens, 2006). During the DCIS to IDC transition, there is significant 
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upregulation of extracellular matrix components and metalloproteases in the stromal 
compartment, suggesting that ECM remodeling is an important part of the transformation 
process (Ma et al., 2009). In response to the primary tumor, the stroma often undergoes a 
desmoplastic response with increased deposition of ECM. The conversion of normal fibroblasts 
to carcinoma-associated fibroblasts is a major contributor of ECM deposition (Elenbaas and 
Weinberg, 2001). Collagen deposition results in increased stiffness of the breast during the 
transition from normal to premalignant to invasive cancer, which along with changes in other 
mechanical properties affects cell signaling and behavior. Inhibition of collagen cross-linking 
delays tumor onset and decrease tumor incidence (Levental et al., 2009; Yu et al., 2011).  
Although gene expression changes are evident in all cell types comprising the tumor, 
genetic mutations are mainly found in the epithelial fraction, suggesting paracrine activation of 
stromal cells (Allinen et al., 2004; Hu et al., 2005). However, genetically abnormal stroma can 
initiate tumors or increase the mutation rate in adjacent epithelial cells (Radisky et al., 2005). 
Paracrine signals from cancer-associated fibroblasts (CAFs) promote tumor growth in non-
tumorigenic and pre-malignant epithelial cells (Olumi et al., 1999; Shekhar et al., 2001; Cheng et 
al., 2005). In a study of gene expression profiles of all cell types in the breast microenvironment, 
DCIS-associated myoepithelial cells exhibited upregulation of genes involved in 
paracrine/autocrine signaling necessary for cell migration (Allinen et al., 2004). In pancreatic 
cancer, increased Hedgehog (Hh) expression in cancer cells results in Hh signaling in the CAFs. 
Therapeutic targeting of only CAFs is sufficient to reduce tumor progression (Yauch et al., 
2008). These results suggest that targeting the more genetically stable microenvironment may be 
more effective than targeting the transformed epithelial cells themselves.  
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1.2 METASTATIC BREAST CANCER 
At most 5% of patients are diagnosed with metastatic breast cancer at presentation, yet around 
30% of patients will be diagnosed with metastases at some point in the course of disease. The 5-
year overall relative survival is a high 98% for those with localized disease to the breast, 83.6% 
for cancer that has spread to regional lymph nodes, and 23% for cancer that has metastasized at 
diagnosis (Altekruse et al., 2010). Recurrence is most common in the first five years after initial 
diagnosis, but relapses can occur as many as 30 years later. Only 2 to 5 percent of those 
diagnosed with advanced disease survive longer than 10 years as the therapies available today 
are mainly palliative, temporary, and not curative.  
Like the pathogenesis of the primary tumor, metastasis results from a complex 
progression of cellular and molecular events. First, the tumor cells detach from the primary mass 
to invade into the surrounding stroma and intravasate into lymph or blood vessels. Secondly, 
following intravasation tumor cells must survive in the circulation and eventually embolically 
arrest in a capillary bed. Third, the cancer cell extravasates out of the vasculature into the 
secondary organ. Finally, these post-extravasation individual or clusters of cells undergo 
apoptosis, lie dormant for an indeterminate length of time, or proliferate to form a micro- and 
then macrometastasis. These steps must all occur in step-wise succession, and as a result, 
metastasis is a highly inefficient process. Failure to complete any one of these steps can prevent 
metastasis, but only a few are considered rate-limiting and contribute to metastatic inefficiency. 
In a chick embryo assay, all cancer cells injected into the circulation survive and extravasate into 
surrounding tissue by 24 hours (Koop et al., 1995), yet only 0.01% of cancer cells injected into 
the circulation form metastatic foci (Fidler, 1970). This was confirmed in rodent models of liver 
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metastases, indicating that post-extravasation survival followed by initial and persistent growth 
of metastatic cancer cells are rate-limiting steps (Luzzi et al., 1998; Cameron et al., 2000). 
1.2.1 Invasion   
Invasion is the first step of the metastatic process. While invasion is necessary for metastasis, the 
finding of invasive or infiltrating cancer cells does not necessarily mean that the cancer has 
metastasized. The ability to invade involves the loss of tumor cell adhesion, processing of the 
ECM, changes in integrin expression, and induction of pro-migratory cell signaling (Wells et al., 
2011). In general, cancer cells employ either single cell or collective cell migration. The mode of 
migration is dependent on differences in extracellular proteases, integrin-mediated cell-matrix 
adhesion, cadherin-mediated cell-cell adhesion, cell polarity, and cytoskeletal arrangement 
(Yilmaz and Christofori, 2010). Even within single cell motility, intravital imaging has revealed 
that there are very motile single cells and slower collectively moving cells, and that the mode of 
motility determines spread through the blood or lymphatic system (Giampieri et al., 2009). 
For single motile cells, there are two forms of migration: mesenchymal-like or amoeboid. 
Mesenchymal-like migration follows employment of cancer-associated epithelial to 
mesenchymal transition (EMT), which will be discussed in detail in Section 1.4. Amoeboid 
migration is characterized by limited interaction with the ECM and independence from 
extracellular proteases. This type of movement is exhibited by immune cells and is often 
observed in hematopoietic malignancies. Cancer cells can switch quickly between these two 
modes, and specific GTPases, Rac or Rho, determine the mode of migration (Sanz-Moreno et al., 
2008). Collectively motile cells, on the other hand, invade with cell-cell adhesions intact. 
Invasion can occur as strands, clusters, sheets or tubes and is usually led by a subset of cells at 
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the front that generate enough force to pull the cells at the rear. This type of migration requires 
extensive degradation of the ECM (Wolf et al., 2007).  
Chemokines and cytokines secreted by cells in the tumor microenvironment are also 
involved in the induction of cell motility during invasion by producing a chemoattractant 
gradient. One of the best-described examples is that of the tumor-associated macrophages 
(TAM) that chemotax breast cancer cells in reciprocal paracrine signaling of CSF-1 and EGF 
(Wyckoff et al., 2004; Patsialou et al., 2009). The onset of invasion also coincides with changes 
in ECM structure and composition. The ability of cancer cells to alter the stromal 
microenvironment correlates with the tumor invasive potential (Li et al., 2009; Soikkeli et al., 
2010). Cancer cells induce gene expression changes in fibroblast and other stromal cells to 
produce ECM molecules that promote tumor migration and increase MMP production to loosen 
the stiffness of the matrix (Gallagher et al., 2005; Adam et al., 2006). Various ECM proteins are 
upregulated in invasive carcinomas, including collagens I and IV, laminins, tenascin C, 
fibronectin and vitronectin. Modulation of cell motility is achieved by varying the expression of 
adhesive and anti-adhesive ECM proteins as well as their ligands. The release of embedded 
growth factors following proteolytic cleavage of ECM components provides a positive feedback 
loop to augment motility (Friedl and Wolf, 2010).  
1.2.2 Intravasation  
Intravasation is the process of entering the circulation, and can occur into the blood or 
lymphatics. Increased tumor size correlates both with lymph node involvement and distant 
metastases (Carter et al., 1989). Intravital imaging has revealed that although both metastatic and 
non-metastatic cells may be motile, metastatic cells exhibit greater polarization toward blood 
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vessels, which is generated by a chemoattractant EGF gradient released by macrophages lining 
the vasculature (Condeelis et al., 2000; Wyckoff et al., 2000). Intravasation into the lymphatic 
system may be more passive than hematogenous dissemination, as lymphatics lack tight 
junctions, layers of pericytes, and basement membranes observed in endothelial cells. The 
leakiness and low pressure of the lymphatic vessels seem to favor amoeboid-like and collective 
migration (Byers et al., 1995). Interestingly, inhibiting lymphatic spread has no affect on distant 
metastasis, suggesting different mechanisms (Wong and Hynes, 2006). 
The mechanisms for intravasation and extravasation are similar. During the 
transendothelial migration of hematogenous dissemination, the cancer cell must break the bonds 
of intercellular adhesion formed by VE-cadherin between endothelial cells (Sandig et al., 1997). 
Expression of N-cadherin has been shown to be necessary for cancer cell adhesion to endothelial 
cells, which upregulates Src and causes the down-regulation of VE-cadherin on the attached 
endothelial cell (Qi et al., 2006). During prolonged heterotypic ligation of cancer cells and 
endothelial cells, activation of Src leads to phosphorylation of N-cadherin, facilitating the 
temporary dissociation of β-catenin and consequently migration across the endothelial barrier. 
The generation of fibrosarcoma cell variants that differ in their ability to intravasate, but not in 
ability to form primary tumors or metastases, has revealed additional cell-surface molecules 
involved in intravasation: cell adhesion molecules N-CAM and JAM-C, and tissue factor, a 
surface receptor active in the coagulation cascade (Conn et al., 2008). An in vitro model of 
intravasation using MDA-MB-231 cells and HUVEC cells separated by a transwell filter showed 
that transendothelial migration induced apoptosis in HUVEC cells (Peyri et al., 2009).  
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1.2.3 Survival in circulation   
Following intravasation, metastatic cells must survive in the circulation by evading anoikis, or 
detachment-induced cell death. Metastatic and non-metastatic melanoma cells are separated by 
their ability to evade apoptosis upon arrest in the vasculature (Kim et al., 2004). Normally, 
attachment to the ECM by integrins is necessary for survival of mammary epithelial cells (Streuli 
and Gilmore, 1999). Furthermore, not just any attachment is sufficient; mammary epithelial cells 
undergo apoptosis on fibronectin or collagen-coated surfaces but survive on laminin-rich 
surfaces reminiscent of the basement membrane (Boudreau et al., 1996). The EMT that enables 
dissemination results in disruption of polarity and unfettered growth factor signaling and loss of 
E-cadherin is sufficient to induce anoikis (Grossmann, 2002).. Excessive growth factor 
stimulation induces cell rounding and anoikis, applying selection pressure on the cancer cell to 
develop resistance to anoikis (Frisch and Screaton, 2001). Constitutively active FAK signaling 
upstream of integrin signal transduction can increase resistance to anoikis (Frisch and Ruoslahti, 
1997). Other mechanisms of evasion include upregulation of the caspase inhibitors XIAP or 
FLIP or increased degradation of the pro-apoptotic protein Bim (Simpson et al., 2008). Inhibition 
of FLIP or XIAP does not prevent orthotopic growth but prevents metastases when cancer cells 
are injected into the circulation  
Circulating tumor cells (CTCs) can be detected in the blood of breast cancer patients, 
even before the presentation of clinical metastases and even in some cases of DCIS (Ignatiadis et 
al., 2011). However, the presence of detectable CTCs in the bloodstream indicates that a large 
number of cancer cells are shed, with one study estimating this figure at 4x106 cells per gram of 
tumor released daily (Butler and Gullino, 1975). Whether or not detection of CTCs is prognostic 
for metastasis is still up for debate (Braun and Naume, 2005; Harris et al., 2007). Furthermore, 
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once disseminated, CTCs do not remain in the circulation for long, as demonstrated by the chick 
chorioallantoic membrane assay for metastasis where almost 90% of cells had extravasated 3 
days after injection (Luzzi et al., 1998).  
1.2.4 Extravasation  
In the circulation, tumor cells arrest in organ capillary beds due to size restriction or 
embolization following binding to coagulation factors. Although mechanical entrapment of 
circulating tumor cells can occur, tumor cells must also adhere to the vasculature and 
extravasate, or transmigrate through the endothelium into organ parenchyma. While the 
mechanisms behind intravasation and extravasation are similar, studies suggest that they are not 
identical. Cellular motility mediated by the tetraspannin CD151 was found to be necessary for 
both intravasation and for migration within the secondary site, but not for extravasation (Zijlstra 
et al., 2008). 
The process of extravasation is similar to diapedesis exhibited by leukocytes in 
inflammation. During diapedesis, leukocytes adhere to and roll along the vasculature and then 
migrate between endothelial cells. The initial attachment of cells to the endothelium is mediated 
by a class of cell adhesion molecules called selectins, followed by stronger adhesions facilitated 
by immunoglobulin adhesion molecules, integrins and cadherins. Expression of many of these 
same cell adhesion molecules are necessary for extravasation of disseminated carcinoma cells 
(Glinskii et al., 2005). Cancer cell rolling mediated by selectins has been observed in vitro 
(Giavazzi et al., 1993; Hsu et al., 2011; Myung et al., 2011). 
Selectins are a family of adhesion receptors that bind to carbohydrate ligands. 
Presentation of selectin ligands on cancer cells is believed to be critical to extravasation. 
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Interactions of circulating cancer cells with platelets and leukocytes via P- and L-selectins may 
support tumor cell embolic arrest and immune evasion in the vasculature (Paschos et al., 2009). 
Cancer cell binding to E-selectin on endothelial cells is critical to the extravasation of colon 
cancer cells in metastatic colonization of the liver. Attachment of cancer cells to the endothelium 
and subsequent formation of metastases can be inhibited by addition of antibodies against E-
selectin (Brodt et al., 1997). Furthermore, selectin-dependent adhesion to endothelial cells results 
in morphology changes, reorganization of the cytoskeleton, and tyrosine phosphorylation, 
suggesting that these interactions are not limited to adhesion and may have downstream 
signaling effects (Di Bella et al., 2003). Differential expression of selectin ligands can also 
influence the site of metastastic colonization and account for organotropism (Gout et al., 2008). 
Following the attachment initiated by selectin binding, other adhesion molecules may 
further strengthen adhesion between cancer cells and endothelial cells. Expression of 
immunoglobulin cell adhesion molecule (IgCAM) family members ICAM and VCAM has been 
observed in distant metastases of colorectal cancer. The attachment of metastatic cells to 
endothelial cells and to extracellular matrix is necessary for metastasis (Schmidmaier and 
Baumann, 2008). The cadherin switch that sometimes occurs during EMT results in the down-
regulation of E-cadherin and the upregulation of N-cadherin. N-cadherin expression on 
endothelial cells may facilitate the heterotypic binding of cancer cells to endothelial cells. 
Indeed, N-cadherin has been shown to mediate attachment of MCF-7 breast cancer cells to 
endothelial monolayers as well as the transendothelial migration of melanoma cells (Sandig et 
al., 1997; Hazan et al., 2000).  Similarly, exogenous expression of gap junction molecule 
connexin 43 (Cx43) in MDA-MET, a breast cancer cell line variant that is highly metastatic to 
bone, results in increased adhesion to endothelial cells. Others have shown similar heterophilic 
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binding between cancer cells and endothelial cells in melanoma and lung cancer (el-Sabban and 
Pauli, 1994; Ito et al., 2000). Finally, engagement of integrins expressed on cancer cells 
contributes to adhesion to the microvasculature, as antibodies against β1, α2, and α6 integrins 
inhibit adhesion to and migration through sinusoids in colorectal metastases to the liver (Enns et 
al., 2004). Although cancer cells may arrest in capillaries due to size-restriction, these studies 
show that adhesion to endothelial cells is nonetheless a required step of extravasation.  
1.2.5 Colonization  
Once integrated into the parenchyma, the stimulation or inhibition of tumor growth can be 
affected by the specific growth factor milieu in the organ, which will be discussed further in 
Section 1.2.6.2. Once in the new receptive organ, metastatic cancer cells can undergo apoptosis, 
become dormant, or proliferate (Fidler, 2002). Dormancy occurs as single or clusters of cells in a 
state of quiescence –not slow growing, as studies suggest that rapid growth upon emergence 
from dormancy is more likely rather than continual slow growth (Demicheli et al., 2007). 
Interestingly, there is a bimodal distribution of recurrence, with a peak at 2 years post diagnosis 
and another at 5 years, which is across the board for all organ sites, suggesting that dormancy is 
the product of something intrinsic within the cancer cell, not the site of metastasis (Demicheli et 
al., 2008). Dormant, viable cells can be isolated from metastasis-free organs in vivo and then go 
on to generate tumors in other animals (Naumov et al., 2002; Suzuki et al., 2006). The factors 
that determine post-extravasation survival over dormancy or cell death are still unknown. Studies 
have shown Ras overexpression is one factor that is necessary to tip the proliferation:apoptosis 
ratio in favor of proliferation to make the transition from micro to macrometastases (Varghese et 
al., 2002).  
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1.2.6 Seed and soil hypothesis 
Stephen Paget observed as early as 1889 that cancers display a characteristic pattern of 
metastasis -- that some tumors have a proclivity for forming metastases in certain organs. He 
termed his explanation for this the “seed and soil” hypothesis (Paget, 1889). In breast cancer, the 
most common sites of distant metastases are bone, liver, lung, and brain. This pattern of 
metastases cannot be explained solely by mechanical arrest in the first capillary bed encountered 
after leaving the breast (Tarin and Price, 1981; Tarin et al., 1984; Glinskii et al., 2005). Rather, it 
has been proposed that the ability of the cancer cells, or “seeds”, to survive and to proliferate in 
the secondary organ is dependent on appropriate signals and supportive environment, or the 
“soil” (Fidler, 1970). The heterogeneous nature of tumors suggests that cells within a primary 
tumor have different metastatic properties in that some may be more targeted to certain organs 
while others have lower metastatic potential overall (Fidler and Kripke, 1977; Hart et al., 1981). 
The histopathology of the primary tumor has been shown to be associated with the specific site 
of metastasis: extent of fibrosis is associated with bone metastases, tumor necrosis and ER/PR 
negative status with lung, and 10 or more nodal metastases with liver metastases (Hasebe et al., 
2008).  
1.2.6.1  The Seed  
The notion of the “seed” is that cancer cells exhibit intrinsic heterogeneity that predispose to 
sites of metastasis or may express molecules to home to specific organs. Examples of this are the 
overexpression of CXCR4, integrins, and other adhesion molecules that allow selective homing 
and migration to bone (Woodhouse et al., 1997; Roodman, 2004). Cancer cells often engage in 
molecular mimicry in which they secrete parathyroid hormone-related protein (PTHrP), which 
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activates osteoclast-mediated degradation of bone matrix, resulting in the release of growth-
stimulating factors that create a vicious cycle of cancer cell growth and the release of more 
PTHrP (Steeg, 2006). Chemokines CXCR3 and CCR7 are highly expressed in cancer cells and 
involved in homing to lung, bone, and lymph nodes, where the ligands CXCL12/SDF-1 and 
CCL21 are expressed. Similarly, CXCR4-expressing breast cancer cells respond to the high 
CXCL12 activity in lung tissue, helping to explain the lung specificity seen in breast cancer 
metastasis. Blocking presentation of the ligand reduces lung metastasis in vivo (Muller et al., 
2001). 
Within tumors a subset of cells are genetically programmed to metastasize to certain 
sites. For example, increased hypoxia in the primary tumor generates a hypoxia response 
signature that primes for metastasis to the lungs (Lu et al., 2010). Variants of the MDA-MB-231 
cell line that exhibit tropism to metastasize to the bone or lung have been isolated (Minn et al., 
2005). Microarray analysis of their gene expression profiles reveals a lung metastasis signature 
and a bone metastasis signature that are distinct from the poor prognosis signature (Van't Veer et 
al., 2002; Kang et al., 2003; Minn et al., 2005). Genes differentially expressed by lung metastasis 
variants include the cell adhesion molecules SPARC and VCAM2, the chemokine CXCL1, and 
metalloproteases MMP1 and MMP2. Similarly, the bone metastasis variant demonstrates 
upregulation of CXCR4, activator of osteoclast differentiation interleukin-11, and osteopontin, 
which promotes osteoclast adhesion to bone matrix. These variants were also found to be pre-
existing in the parental population and selected for in vivo. To demonstrate that the propensity to 
metastasize to one organ over another is intrinsic, fusion of the two cell variants generates clones 
that have dual organotropism (Lu and Kang, 2009).  
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1.2.6.2  The Soil  
The soil aspect of the seed and soil hypothesis posits that the specific organ microenvironment 
supports tropism. For example, the bone microenvironment is considered “fertile”, as it is rich 
with growth factors bound to the bone matrix that are released upon degradation by osteoclasts. 
These growth factors such as EGF and VEGF cause selective growth of cells that metastasize to 
bone (Woodhouse et al., 1997). In the brain, astrocytes abundantly secrete cytokines such as IL-
1, IL-3, IL-6, TNFα, IGF-1, and PDGF-1, of which tumor cells take advantage to increase their 
survival and growth (Lu and Kang, 2007). The ECM and conditioned media of liver 
parenchymal cells has also been shown to preferentially stimulate the growth of cancers that 
metastasize there (Zvibel et al., 1998). 
Changes in the microenvironment, through the infiltration of immune cells, matrix 
remodeling, and increases in reactive oxygen species have been observed in distant organs prior 
to metastasis, suggesting that the preparation of a premetastatic niche may contribute to organ-
specific metastasis (Kaplan et al., 2006). Infiltration of bone marrow-derived hematopoietic 
progenitor cells (HPCs) are found in the premetastatic niche, prepping the “soil” for 
extravasating cancer cells. The HPCs are mobilized to the premetastatic niche by factors secreted 
by cancer cells, which is cell-type specific. Conditioned media from Lewis lung carcinoma 
(LCC) cells results in clustering of HPCs in lung and liver while conditioned media from B16 
melanoma cells results in mobilization to lung, liver, testis, spleen and kidney, all common sites 
of melanoma metastasis.  Interestingly, LLC cells can be reprogrammed to metastasize to the 
sites observed by B16 melanoma cells by preconditioning with B16 conditioned media. 
Furthermore, these HPCs express VEGFR and secrete MMP9 to degrade the basement 
membrane to allow for further infiltration and to alter the local microenvironment, making it 
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more suitable for tumor cell attachment, survival, and growth. Clusters of VEGFR+ cells have 
been observed in human tissue in common sites of metastasis in the absence of tumor (Kaplan et 
al., 2005). However, the use of monoclonal antibodies to block VEGFR does not affect 
metastatic tumor growth in vivo, suggesting that there are alternate pathways (Duda and Jain, 
2010).   
1.2.7 Liver metastases   
The liver is the most common site of metastases, so much that liver metastases are more common 
than primary hepatic tumors. The liver is not a common initial site of metastases but 40-75% of 
women diagnosed with metastatic breast cancer will present with liver metastases at some point 
during the course of disease (Viadana et al., 1973; Lermite et al., 2010). The median survival of 
breast cancer patients diagnosed with only liver metastases is less than 25 months and decreases 
to 15.5 months when metastases at other organ sites are also present (Atalay et al., 2003). Liver 
metastases present stealthily, with abdominal pain, hepatomegaly, or abnormal liver function 
values as the main clinical symptoms. Only a few patients will present with the more noticeable 
symptoms of ascites or jaundice.  
Grossly, the liver consists of four lobes and is supplied by the hepatic artery and portal 
vein, which drains the spleen and gastrointestinal system. Blood flows through the sinusoids and 
empties into the central vein of each lobule. Hepatocytes are the epithelial cells that constitute 
around 70% of the liver, and are organized in plates a single-cell thick along sinusoids. 
Fenestrated endothelial cells that lack basement membranes, a unique feature of the liver, line 
sinusoids.  The space of Disse, which drains lymph, provides a separation between hepatocytes 
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and sinusoids. Kupffer cells are scattered between endothelial cells and phagocytose red blood 
cells. Stellate cells produce ECM and actively respond to liver injury by secreting collagen.  
In general, liver metastases exhibit several patterns of growth. Desmoplastic lesions are 
separated from the parenchyma by a fibrotic ring and do not conserve the existing liver 
architecture. In the “pushing” pattern of growth, which is similar to desmoplasia but without 
fibrosis, tissue architecture is also not conserved. In the replacement pattern, cancer cells take the 
place of hepatocytes and co-opt the existing vasculature, conserving tissue architecture. Breast 
cancer liver metastases most commonly exhibit the replacement pattern. Hypoxia and 
angiogenesis thus occur much later compared to other modes of tumor growth (Stessels et al., 
2004).  
Not much is known about the signals from the liver that promote colonization but there 
are several features unique to the liver that may contribute to a ripe environment for metastases. 
First, fenestration of the sinusoid endothelium may allow for easier extravasation and access into 
the parenchyma. In addition, factors secreted by liver sinusoidal endothelium and not lung 
endothelium induce the motility of metastatic cancer cells (Sawada et al., 1996). Likewise, 
Kupffer cells of the monocyte lineage secrete soluble and matrix factors trophic for cancer cells 
(Wyckoff et al., 2004). The unique composition of the liver ECM also plays a role, as it has been 
shown that organ-specific metastasis correlates with the ability for cancer cells to survive on 
organ-derived matrix (Doerr et al., 1989). Heparin proteoglycans in the liver ECM regulate 
autocrine EGF activation in colon cancer cells and hepatocyte-derived growth factors strongly 
stimulate the growth of highly liver metastatic cells (Zvibel et al., 1998). In vivo selection for a 
liver-aggressive variant of 4T1 breast cancer cells revealed that claudin-2 is upregulated in liver 
metastases and improves adhesion of liver-aggressive cells to fibronectin and collagen IV, key 
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components of the liver ECM, through increased recruitment of α5β1- and α2β1-integrin 
complexes (Tabaries et al., 2010).  
Invasive breast carcinomas have been shown to express higher levels of hepatocyte 
growth factor (HGF) and its receptor MET (Jin et al., 1997) when compared to ductal carcinoma 
in situ. Comparative proteomic analysis of variants of the metastatic MDA-MB-435 breast 
cancer cell line selected in vivo for metastasis to the lung or to the liver revealed a panel of 
proteins that were differentially expressed in liver but not lung metastases that included 
pathways involving HGF, PDGF, VEGF, and EGF (Martin et al., 2008). Similar to the primary 
tumor microenvironment, metastasis-associated fibroblasts also express different gene 
expression profiles compared to normal liver fibroblasts or fibroblasts derived from other organs, 
which include the up-regulation of many adhesion molecules such as VCAM, ICAM, K-
cadherin, and N-cadherin (Nakagawa et al., 2004).  
1.2.8 Experimental models of metastasis 
As ethical constraints prevent testing in humans, most in vivo studies of metastasis are 
performed in immunocompromised mouse or rat animal models. There are two well-established 
methods of studying metastasis in animal models: spontaneous and experimental metastasis. In 
spontaneous metastasis, breast cancer cells are injected at the orthotopic site, or the mammary fat 
pad, and allowed to metastasize. All the steps of the metastatic cascade must be completed to 
observe metastases using this method. For experimental metastasis, the steps of invasion and 
dissemination are bypassed as cells are injected directly into the circulation via tail vein, 
intracardiac, or intrasplenic injection.  
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The use of immunocompromised animal models is necessary for human cell inoculation, 
but then the role of the immune system cannot be ascertained. Another issue with animal studies 
is that the specific pattern of metastasis observed in humans is either not always replicated in 
animal models or may be limited by other factors. For example, because the liver is not usually 
the site of initial metastases, most experiments are ended prior to observation of liver metastases 
due to excessive tumor burden. Finally, animal studies are end-stage in that the endpoints are 
whether metastases develop or do not develop, thus preventing observation of the actual process.   
Intravital or in vivo imaging techniques seek to overcome this problem. Whole body 
imaging using bioluminescence or fluorescence enables the detection of developing metastases 
in the same animal over time. Imaging at the single cell level through an imaging window and 
imaging using multiphoton confocal microscopy have provided insights into cell motility and 
invasion during intravasation and extravasation, but is technically limited by depth of field and 
length of time of observation (Sahai, 2007; Kedrin et al., 2008). Imaging of biological processes 
in tumors can exploit reporter gene or GFP-tagged proteins to investigate molecules or pathways 
of interest in vivo. Probes to detect MMP activation, apoptosis, and hypoxia have been used 
(Bouvet et al., 2006; Sahai, 2007). Using a GFP transgenic mouse and color-coded tumor and 
stromal cells, the recruitment of fibroblasts to the metastatic tumor microenvironment was 
observed in the liver in real time (Suetsugu et al., 2010). 
Given that liver metastases in animal models are not commonly observed, organotypic 
bioreactors are a viable option. 2D culture of isolated primary hepatocytes is limited because of 
the quick loss of liver-specific functions. Expression of important liver enzymes is lost within 
one day of in vitro adherent culture of primary hepatocytes. Liver tissue slices have been used, 
but without perfusion, areas of the slice become quickly necrotic (Cross and Bayliss, 2000). In 
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3D culture, hepatocytes form spheroid aggregates that can include non-parenchymal cells and 
extracellular matrix components. Liver bioreactors are such an improvement over 2D cultures 
that their use has been considered for extracorporeal liver support for those awaiting transplant 
(Sauer et al., 2003; Gerlach, 2006).  Primary hepatocytes cultured in a 3D perfused bioreactor 
maintain a phenotype much closer to hepatocytes in vivo in terms of both gene expression 
profiles and drug metabolism (Sivaraman et al., 2005). These bioreactors are designed to mimic 
physiologic fluid stress experienced in the liver. In many cases, imaging in real-time is possible 
(Powers et al., 2002). Non-parenchymal cells (NPCs) can also be introduced, as ECM and 
interactions with NPCs undoubtedly affect hepatocyte function. The ability to add NPCs enables 
layers of complexity to probe the metastatic process (Zeilinger et al., 2004; Hwa et al., 2007).  
1.3 TREATMENT  
Tumor stage, histology and ER/PR/HER2 marker expression are a constellation of factors that 
affect the course of treatment for the primary tumor. If the tumor has not spread to surrounding 
lymph nodes or distant organs, local resection with radiation is usually sufficient. Chemotherapy 
prior to surgical resection may be indicated for large tumors to shrink the tumor. Otherwise, 
adjuvant systemic therapy is clinically indicated following surgical removal for most node-
negative and node-positive cancers. Systemic therapy can include any combination of 
chemotherapy, hormone therapy (such as tamoxifen or an aromatase inhibitor), or HER2-
targeted monoclonal antibody (trastuzumab or Herceptin), depending on ER, PR, and HER2 
status (Goldhirsch et al., 2009).  
For breast cancer liver metastases, surgical resection is only indicated for isolated 
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metastases. Isolated metastases are observed in 5% of patients with liver nodules, and post-
resection there is a 50% recurrence rate. Thus the survival rate of patients presenting with 
metastatic nodules in the liver is low (Lubrano et al., 2008; Lermite et al., 2010). The high rate of 
post-hepatectomy tumor recurrence may be explained by growth factor release (HGF, EGF, and 
VEGF) and ECM remodeling that occurs during liver regeneration following hepatectomy, 
which may promote the growth of dormant metastases (Paschos and Bird, 2010). Because most 
patients present with multiple liver metastases, systemic chemotherapy is therefore indicated, 
which can be combined with transarterial chemoembolization (TACE) to more directly target the 
liver. Even still, systemic chemotherapy and endocrine therapy only have a 60% response rate.  
Methods of palliation of liver metastases include radiofrequency ablation, selective internal 
radiotherapy (SIRT) using resin microspheres labeled with Yttrium-90, or stereotactic body 
therapy (SBRT)  (Lubrano et al., 2008; Lermite et al., 2010). These treatments are palliative but 
do not prevent progression (Diamond et al., 2009). Although initially promising, antiangiogenic 
drugs such as Avastin (VEGF-A inhibitor) have had little clinical success. For breast cancer liver 
metastases specifically, the replacement pattern of liver metastatic growth in which existing 
vessels are co-opted in place of angiogenesis, suggests that anti-angiogenic therapies may not be 
beneficial on micrometastases (Stessels et al., 2004). 
1.3.1 Personalized medicine/ Targeted therapies 
While ER/PR/HER2 status provides a guideline for treatment, within each group there is still a 
large amount of heterogeneity of response to therapy. Thus efforts are turning to more closely 
tailored therapy based on the molecular profile of each patient’s tumor. While the classification 
of tumors into molecular subtypes has yet to directly influence clinical treatment, gene 
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expression profiles or molecular signatures are being used to predict outcome and response to 
treatment in a subset of tumors. These gene signatures are used to predict response to additional 
adjuvant systemic therapy and are not used in place of traditional clinical factors. Oncotype DS 
and MammaPrint are the most well-validated of these molecular profiling prognostic assays. 
Oncotype DS uses a 21-gene signature to predict low, intermediate, or high risk of recurrence 
rate in node-negative, ER-positive tumors. The MammaPrint assay uses a 71-gene signature that 
requires fresh tissue and identifies low and high risk of relapse (Harris et al., 2007).    
1.3.2 Chemoresistance 
Tumors can be intrinsically resistant to chemotherapy or acquire resistance over the course of 
treatment. Even within ER+ and HER2+ tumors, not all tumors respond to endocrine therapy or 
Herceptin. Gene profiles delineating the responders from the non-responders are being developed 
to predict which patients will have therapeutic success. Little is known about the specific 
mechanisms behind both intrinsic and acquired chemoresistance, but because of genetic 
instability of cancer cells, selection pressure can lead to adaptations promoting resistance: drug 
efflux, drug inactivation, mutation of drug targets, DNA repair, activation of survival signaling, 
and evasion of apoptosis (Wilson et al., 2006). Overexpression of ATP-binding Cassette (ABC) 
transporters such as P-glycoprotein has been observed in cancer cells resistant to common 
chemotherapy drugs like camptothecin, vincristine, and 5-fluorouracil (5FU). Many drugs must 
be converted to active forms using endogenous enzymes and cancer cells can become resistant 
by decreasing expression of these enzymes or by increasing expression of enzymes that increase 
clearance or inactivation. Similarly, mutation or overamplification of the drug target also occurs. 
For example, cell lines resistance to 5FU exhibit overexpression of target thymidylate synthase. 
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Increased expression of DNA damage repair proteins leads to resistance to drugs whose 
mechanism of action is DNA damage. Over-expression of anti-apoptotic proteins like Bcl-2 or 
decreased expression of apoptotic proteins like Fas or p53 are common methods of mediating 
drug resistance. Conversely, overexpression of protein tyrosine kinases that activate pro-survival 
pathways like Akt and Erk are alternative mechanisms of chemoresistance.  
Under the cancer stem cell hypothesis, one of the prevailing explanations for the 
chemoresistance observed in cancer is that current therapies are cytotoxic to replicating cells but 
leave slow cycling tumor-initiating cells intact (Chuthapisith et al., 2010). Stem cells are also 
loaded with multiple drug transporters, enhancing drug efflux. If cancer stem cells are 
responsible for generating tumors and metastases, finding effective cancer therapies is a 
qualitative versus a quantitative problem, as killing the bulk of the tumor will have little effect. 
Recently, high-throughput screens have isolated several compounds that selectively target the 
small population of tumor-initiating cells (Gupta et al., 2009).  
Given the role of the microenvironment in tumorigenesis and metastatic progression, it is 
not surprising that interactions with stromal cells facilitate chemoresistance. In metastases of 
melanoma and breast cancer to the brain, interactions with astrocytes increase chemoresistance 
(Lin et al., 2010). Stromal ECM protects colon cancer cells from cell death induced by 
camptothecin or etoposide while collagen I, fibronectin and fibroblast-derived ECM increase the 
chemosensitivity of cancer cells to 5-FU (Kouniavsky et al., 2002). Hypoxia of the tumor 
microenvironment also increases the radio- and chemoresistance of tumors (Brown and Wilson, 
2004). With both intrinsic and extrinsic contributions to chemoresistance and cancers often 
exhibiting multidrug resistance, developing effective therapeutics is clearly a difficult task. 
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1.4 EPITHELIAL TO MESENCHYMAL TRANSITION 
One mechanism that is important to metastatic progression is the re-employment of epithelial-
mesenchymal transition (EMT). During EMT, cells lose apico-basal polarity, gain motility, and 
lose cell-to-cell contacts through the loss of cadherins and other specialized structures for 
adhesion, allowing for the detachment and dissemination of cancer cells (Thiery, 2002; Tse and 
Kalluri, 2007). EMT is a program deployed during embryonic development that is required for 
gastrulation as well as morphogenesis of the neural crest, musculoskeletal system, craniofacial 
structures, and the peripheral nervous system (Thiery, 2002). EMT is also utilized in adult 
physiological processes such as wound healing, where keratinocytes undergo a process akin to 
EMT during re-epithelialization of the wound, as well as pathological processes such as kidney 
fibrosis, idiopathic pulmonary fibrosis, and cataract formation in the lens (Thiery and Sleeman, 
2006). As there are subtle differences between the pathologic and physiologic phenotypic 
transitions, EMT is now classified as developmental EMT, fibrosis-associated EMT, and cancer-
associated EMT (Kalluri and Weinberg, 2009). The cancer-associated EMT is more loosely 
defined as plasticity exhibited by an epithelial cell rather than as true differentiation into a 
mesenchymal cell. 
There is increasing evidence for the role of EMT in tumor progression. Many studies 
have shown that tumor progression and poor prognosis correlate with expression of proteins 
characteristic to mesenchymal cells, such as vimentin, fibronectin, and matrix 
metalloproteinases, as well the down-regulation of proteins typical to epithelial cells such as E-
cadherin (Thiery and Sleeman, 2006). In addition, comparison of large-scale transcriptional 
profiles of cells from metaplastic breast carcinoma, a highly invasive and metastatic subtype of 
breast cancer, with cells from ductal carcinoma, a less metastatic subtype, showed differential 
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overexpression of several genes involved in EMT (Lien et al., 2007). This implies that genes 
responsible for the phenotypic switch can also promote invasion and metastasis. Expression of 
genes that induce EMT enhance the metastatic potential of tumor cells in vivo (Grunert et al., 
2003). Cell fate mapping strategies and methods to differentially mark epithelial and stroma cells 
provide direct in vivo evidence for the occurrence of EMT (Trimboli et al., 2008). EMT is most 
discernable at the invasive front of primary carcinomas and has been visualized as individual or a 
group of cells migrating into the surrounding tissue (Wyckoff et al., 2000).  
Several critical changes in cell properties and behaviors underline the ability for cancer-
associated EMT to enable metastatic dissemination. These include the loss of cell-cell adhesions 
that physically tether cancer cells together, sequester molecules that would otherwise activate 
invasive signaling pathways, and prevent inappropriate growth factor signaling. Following loss 
of cell adhesion, the emancipated cancer cell then penetrates the basement membrane and 
actively migrates into the surrounding stroma, supported by proteolytic degradation of the matrix 
(Wells et al., 2011).   
1.4.1 Loss of cell adhesion  
One of the main distinguishing characteristics of epithelia is that epithelial cells are linked by 
cell adhesion molecules to form contiguous sheets. These intercellular physical interactions not 
only limit motility but also establish apico-basal polarity that regulates signaling between cells 
and the surrounding environment. In contrast, mesenchymal cells exhibit transient and 
changeable front-back polarity and present loose and readily tractable intercellular contacts. As 
an important mediator of the transformation between epithelial and mesenchymal phenotypes 
during EMT, loss of cell adhesion molecules has been repeatedly documented to be associated 
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with invasion and poor prognosis in many carcinomas. Loss of cell-cell adhesions is a critical 
step during EMT that allows for physical detachment of individual or groups of cancer cells from 
the primary tumor and for autocrine activation of signaling pathways that enable migration. 
There are four main types of cell-cell junctional molecules that connect epithelial cells. 
Tight junctions provide a barrier for solutes and small molecules along the apical surface of cells. 
Adherens junctions provide strong mechanical cohesion through connection to the actin 
cytoskeleton. Desmosomes also mediate intercellular contacts, but through anchorage to 
intermediate filaments. Gap junctions form intercellular junctions that allow the passage of ions 
and small molecules. In addition, integrins are cell-substratum adhesion molecules that are 
located on the basal surface of epithelial cells and facilitate interactions between the ECM and 
the cytoskeleton.  Members of all these different families of cell adhesion molecules act in 
concert to contribute to a fully polarized epithelial phenotype. 
Components of each one of these cell adhesion molecules have been shown to be 
dysregulated during invasion. Cadherins, the main component of adherens junction, will be 
discussed in depth in Section 1.5, particularly the epithelial cadherin, E-cadherin. Dissolution of 
tight junctions is an early event in EMT and several tight junction components are dysregulated 
in cancer progression. Expression of occludin in breast cancer cells decreases invasion and 
migration in vitro and in vivo (Osanai et al., 2006). Similarly, levels of claudins are 
downregulated in invasive carcinomas and exogenous introduction of claudins increases 
adhesion and prevents migration and invasion (Osanai et al., 2007; Martin et al., 2008). 
Desmosomal components are also commonly downregulated in carcinomas and associated with 
presentation of distant metastases, especially in cancers of the head and neck (Depondt et al., 
1999). Loss of the desmosomal plaque proteins plakophilin-1 and -3 increases cell motility and 
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metastasis of carcinoma cells (Sobolik-Delmaire et al., 2007; Kundu et al., 2008). Transfection 
of desmosomal components desmocollin, desmoglein, and plakoglobin into L929 fibroblasts 
results in intercellular adhesion and suppression of invasion into collagen gels, even in the 
absence of the assembly of full desmosome complexes with linkage to intermediate filaments 
(Tselepis et al., 1998). Lastly, inhibition of cell motility of prostate carcinoma and melanoma 
cells correlates with increased localization of gap junction molecule connexin 43 (Cx43) at cell-
cell contacts (Daniel-Wojcik et al., 2008).  
As cancer cells break free from the tumor mass and begin to interact with the 
extracellular matrix, integrins gain importance. Not only do they provide anchorage to the actin 
cytoskeleton and connect the cell to the ECM during migration, but they also transmit outside-in 
signaling. Integrins are composed of α and β subunits that form a heterodimeric complex to 
determine specificity to ligands. Some integrin heterodimers exhibit great promiscuity by 
binding to several different ECM components while others may recognize only unique ligands. 
Epithelial cells typically express the β1 subunits, which recognize collagen and laminin, and the 
epithelial-specific α6β4, αvβ3 integrins (Matlin et al., 2003). Several studies have documented 
the differential expression, distribution, and ligand affinity of integrins in preneoplastic lesions 
and carcinomas. Expression of integrins and therefore adhesion to ECM is regulated by TGF-β, 
which is a potent inducer of EMT (Ignotz and Massague, 1987). TGF-β downstream targets 
Smads activate the expression of integrins and focal adhesion-associated proteins. 
Transformation of mammary epithelial cells with the Ras oncogene induces EMT and the 
upregulation of integrins α2, α3, α5, α6, and β1 and consequently increases adhesion to matrix 
components collagen, fibronectin and laminin 1. EMT and integrin expression changes in these 
Ras transformed cells is maintained by an autocrine TGFβ1 loop (Maschler et al., 2005).  
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1.4.2 Disruption of apico-basal polarity  
Besides tethering cells together to prevent the detachment and migration of cells, tight and 
adherens junctions also establish tissue polarity. This is a critical regulatory mechanism, as most 
epithelial cells secrete growth factors from their apical surfaces but express the cognate receptors 
on their basolateral surfaces (Figure 1). When cell adhesion molecules are disrupted in 
carcinoma-associated EMT, this organization is lost, and the growth factor receptors that are 
located basolaterally can now come into unrestricted contact with their ligands. Furthermore, the 
growth factors now have access to the basement membrane and stromal compartment, and can 
affect changes in the tumor microenvironment to further promote motility. For example, 
induction of EMT through TGFβ1 expression normally leads to increased ECM production, and 
deposition and reconstruction of the basement membrane stops the autocrine loop. However, in 
tumors this feedback loop is disrupted and TGFβ1 is continuously produced and active.  
1.4.3 Induction of cell motility 
Following the loss of cellular adhesion that allows for detachment from the primary tumor mass, 
tumor cells must penetrate the basement membrane and migrate through the surrounding stroma 
to disseminate. As a result of EMT, gene expression changes both regulate the ability of the cell 
to migrate and the production of matrix metalloproteinases to degrade the ECM. Consequently, 
proteolytic degradation of the stroma causes the release of growth factors and other molecules 
that provide feedback signals for further active cell migration, helps to cause turnover of cell 
adhesion molecules, and paves a path through which the cancer cell migrates (Radisky and 
Radisky, 2010).  
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Growth factors such as EGF, IGF, FGF, HGF and TGF-β that are present in the primary 
site can induce EMT and migration in cancer cells. Autocrine and paracrine activation of stromal 
cells and concurrent overexpression of growth factor and chemokine receptors such as EGFR, c-
Met, and CXCR4 in cancer cells augments growth factor stimulation (Yilmaz and Christofori, 
2010). TGF-β1 secreted by cancer cells promotes a pro-migratory environment through paracrine 
signaling to myofibroblasts to induce ECM deposition. Cytokines and chemokines secreted by 
cells in the tumor microenvironment also contribute to cell motility. There is cross-talk between 
many of these growth factors and their receptors, adding overlapping and compensatory levels of 
motility signaling (Lorenzato et al., 2002).  
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Figure 1. Epithelial to mesenchymal transition. Epithelial cells are characterized by 4 types of 
cell adhesion molecules (top). Cancer-associated EMT results in loss of cell adhesion and 
polarity and autocrine growth factor activation (bottom).  
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1.5 E-CADHERIN 
Loss of cell-cell adhesions is a critical step during both developmental and cancer-associated 
EMT that allows for physical detachment of individual or groups of cancer cells from the 
primary tumor. Loss of epithelial-cadherin, or E-cadherin, is widely recognized as the hallmark 
of EMT and is vital for the initiation of tumor invasion and dissemination. Required for epithelial 
morphology, E-cadherin is silenced during EMT as epithelial cells change to a mesenchymal 
phenotype (Takeichi, 1995).  
1.5.1 Function and structure 
E-cadherin is a member of the cadherin classical family of transmembrane glycoproteins that 
mediate calcium-dependent homophilic interactions and is the only cadherin expressed in 
epithelial cells. The other cadherin members most studied besides E-cadherin are N-cadherin 
(neural), R-cadherin (retinal), P-cadherin (placental), OB-cadherin (bone), and VE-cadherin 
(endothelial). Cadherins are the core components of adherens junctions, which are integral to 
tissue homeostasis and to creating polarized sheets of cells through homotypic cell-cell adhesion. 
During morphogenesis, the cell sorting that results in the formation of different layers and 
structures is largely facilitated by cadherins (Hirano et al., 1987). 
The basic structure of a cadherin is an amino-terminal extracellular domain, a 
transmembrane domain, and a carboxy-terminal cytoplasmic domain (Figure 2). The 
extracellular domain consists of 5 repeating units of the EC domain with EC1 being the most 
distal ectodomain and EC5 the most proximal. Recently it has been shown that the EC1 domains 
form trans interactions with EC1 domains on the opposing cell (Zhang et al., 2009). Cis 
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clustering of E-cadherin monomers in the same cell strengthen these trans adhesions. Calcium is 
required for the rigidity of the extracellular domains. The structures of cadherins family members 
exhibit 57% homology in the extracellular domain, which is responsible for the adhesive 
function (Hirohashi and Kanai, 2003). However, the cytoplasmic domain is highly conserved and 
binds to β-catenin and p120, which through binding to α-catenin link the cadherins to the actin 
cytoskeleton. E-cadherin and β-catenin associate in the endoplasmic reticulum and transport to 
the cell surface together. Impairment of β-catenin binding results in degradation of E-cadherin, 
as binding of β-catenin blocks the motif recognized by ubiquitin ligases (Huber et al., 2001). 
Importantly, β-catenin is a nuclear transcriptional co-activator for Wnt signaling and the 
mitogenic LEF/TCF family of transcription factors, so sequestration of this molecule by 
cadherins prevents activation of downstream signaling pathways (Heuberger and Birchmeier, 
2010). 
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Figure 2. Structure of E-cadherin. 
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1.5.2 Role as tumor-suppressor 
As the only cadherin expressed by epithelial cells, E-cadherin has been described as the 
“caretaker” of the epithelial phenotype and thus loss of E-cadherin is central to cancer-associated 
EMT. Downregulation of E-cadherin expression correlates with the progression of most 
carcinomas including breast carcinomas (Oka et al., 1993; Takeichi, 1993; Peinado et al., 2004). 
Generally, E-cadherin expression is present in well-differentiated cancers and reduced in 
undifferentiated, highly invasive cancers. This relationship also correlates with patient survival 
(Umbas et al., 1994). E-cadherin is considered an invasion suppressor, as transfection of invasive 
E-cadherin-negative carcinoma cell lines with E-cadherin cDNA decreases invasiveness, which 
is reversed after treating transfected cells with an anti-E-cadherin function-blocking antibody 
(Frixen et al., 1991; Vleminckx et al., 1991). Loss of E-cadherin is sufficient to increase the 
metastatic behavior of noninvasive breast cancer cells and is a rate-limiting step of the transition 
from adenoma to invasive carcinoma (Perl et al., 1998).  
Perturbation of E-cadherin expression promotes cell motility in several ways. Physical 
adhesion mediated by E-cadherin prevents the dissociation and migration of cells. In addition, E-
cadherin down-regulation releases β-catenin from the membrane, where it can then translocate 
into the nucleus and act as a transcription co-activator in downstream signaling pathways.  
Studies using E-cadherin mutants suggest that the β-catenin binding function and not adhesion is 
responsible for invasion suppression (Wong and Gumbiner, 2003). In addition, loss of E-
cadherin alone is not sufficient to drive β-catenin signaling, so it is likely that E-cadherin 
regulates the threshold of β-catenin signaling (Jeanes et al., 2008). Furthermore, use of a 
dominant-negative E-cadherin that results in subcellular localization and prevents intercellular 
A.1.2  
 38 
contacts is sufficient to induce the invasive phenotype, but expression of a constitutively active 
β-catenin is not (Berx and Van Roy, 2001). 
Although down-regulation of E-cadherin has been shown to be sufficient to induce the 
changes in cell behavior downstream of EMT, in some cases expression of the mesenchymal 
cadherins can be sufficient or dominant. Downregulation of E-cadherin is often, but not always, 
accompanied by an upregulation of N-cadherin suggesting a cadherin switch in EMT (Lehembre 
et al., 2008). However, colocalization of both E-cadherin and N-cadherin has been observed 
(Hazan et al., 2000). In addition, forced expression of N-cadherin in the absence of changes in E-
cadherin has been shown to induce migration and invasiveness of cancer cells either through 
FGFR signaling or through interactions with N-cadherin expressed by the surrounding stromal 
cells. Similarly, expression of R-cadherin in BT-20 breast cancer cells leads to downregulation 
of E- and P-cadherins and induction of cell motility through sustained activation of Rho GTPases 
(Depondt et al., 1999). Although seemingly contradictory, these studies suggest that E-cadherin 
and the mesenchymal cadherins may induce motility via different mechanisms intrinsic to the 
disparate functions of the cadherins.  
1.5.3 Regulation  
The molecular mechanism of E-cadherin suppression in breast cancer is distinct from most other 
tumor suppressor molecules where irreversible genetic deletion or mutation is the rule. Except 
for invasive lobular breast carcinomas and hereditary gastric cancer, few somatic mutations in E-
cadherin are found. Ablation of both E-cadherin and p53 in a mouse model is sufficient to cause 
metastatic infiltrating lobular carcinoma (Derksen et al., 2006). Instead, in most carcinomas E-
cadherin is directly silenced by promoter hypermethylation, which can be reversed by the DNA 
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methyltransferase inhibitor 5-azacytidine in human cancer lines (Yoshiura et al., 1995). 
Methylation of CpG islands in the promoter increases with malignant progression (Graff et al., 
1995; Nass et al., 2000). Importantly, methylation of the E-cadherin promoter is dynamic, and 
can be modulated by the microenvironment or by changes in tissue architecture (Graff et al., 
1997; Graff et al., 2000).  
E-cadherin is silenced by transcriptional repressors Snail, Slug, and Twist. Upregulation 
of these repressors in invasive breast carcinomas correlates with EMT and loss of E-cadherin 
expression (Hajra et al., 2002; Yang et al., 2004; Olmeda et al., 2007). Multiple micro-RNAs are 
specific for these transcriptional repressors, thereby blocking protein translation and resulting in 
increased E-cadherin expression. Many of these micro-RNAs are aberrantly expressed in breast 
cancer (Burk et al., 2008; Tryndyak et al., 2010). Other mechanisms of perturbing E-cadherin 
include increasing endocytosis and degradation via phosphorylation of the cytoplasmic domain, 
which result from activation of proto-oncogenes EGFR, c-Met, and Src (Berx and van Roy, 
2009). Destabilization of binding partners p120 or β-catenin also increases E-cadherin turnover. 
Matrix metalloproteinases and other proteases proteolytically cleave E-cadherin at the 
extracellular domain close to the plasma membrane, resulting in soluble form of E-cadherin that 
act as a dominant negative to antagonize normal E-cadherin ligation (Figure 3). 
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Figure 3. Regulation of E-cadherin in cancer 
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1.6 MESENCHYMAL TO EPITHELIAL REVERTING TRANSITION 
Despite the wealth of studies describing EMT in carcinoma cells in vitro, and the strong clinical 
association between loss of expression of adhesion molecules and invasion and poor prognosis, 
metastases often present a well-differentiated, epithelial phenotype, bringing into question 
whether EMT is reversible. It is well described that signals from the primary tumor 
microenvironment greatly contribute to induction of EMT at the primary tumor, so dissemination 
not only removes cancer cells from these signals but also exposes them to new ones at the 
secondary organ site. Whether the microenvironment at the secondary organ affects the plasticity 
of cancer cells to under a mesenchymal to epithelial reverting transition (MErT) is a question of 
great interest. As evidence of the phenotypic plasticity of cancer cells, PC3 prostate cancer cells 
cultured in 3D Matrigel form cell-cell contacts, tight junctions, and decrease in mesenchymal 
gene expression, suggesting that a change in tissue architecture is enough to induce such 
morphological changes (Lang et al., 2001). 
While the mesenchymal phenotype that results from EMT may promote invasion and 
dissemination, there is evidence that metastatic colonization favors an epithelial phenotype. In 
bladder carcinoma, cell lines selected in vivo for increasing metastatic ability reacquire epithelial 
morphology and gene expression. When these cells are injected orthotopically, they show a 
decreased ability to colonize the lung when compared to the more mesenchymal parental cell 
line. However, when they are injected via intracardiac or intratibial inoculation, they exhibit an 
increased ability to colonize the lung compared to the parental cell line (Chaffer et al., 2006). 
Therefore, while induction of EMT through loss of E-cadherin promotes tumor invasion and 
spread, MErT through E-cadherin re-expression may allow the metastatic cancer cell to complete 
the last steps of the metastatic process and survive in the new organ.  
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A few studies of tumor histopathology suggest that this cancer cell plasticity occurs in 
patients: a number of studies have shown that E-cadherin-positive metastases may derive from 
E-cadherin-negative primary carcinomas (Mayer et al., 1993; Bukholm et al., 2000; Rubin et al., 
2001; Kowalski et al., 2003; Saha et al., 2007). Similarly, changes in β-catenin localization have 
been documented (Brabletz et al., 2001) and a study of breast cancer found increased expression 
of Cx26 and Cx46 in metastatic lymph nodes compared to the primary tumors, with even 
positive foci originating from connexin-negative primaries (Kanczuga-Koda et al., 2006; 
Kanczuga-Koda et al., 2007).  
1.7 HYPOTHESIS 
Even with the abundant evidence for E-cadherin’s role in initiating metastasis through EMT, few 
have looked at E-cadherin expression during the last steps of the metastatic process, particularly 
in colonization of the secondary organ. Given that metastases can look histologically similar to 
the primary tumor, it is possible that the reciprocal process to EMT, or mesenchymal-to-
epithelial reverting transition (MErT), is involved in the establishment of metastases at the 
secondary site. As E-cadherin down-regulation in invasive carcinomas is largely the result of 
promoter methylation and transcriptional repression, cancer cells can easily switch between 
epithelial and mesenchymal phenotypes. Promoter hypermethylation leading to E-cadherin 
suppression is dynamic and reversible and therefore re-expression in response to changes in the 
microenvironment is possible (Graff et al., 2000). The question remains whether the well-
differentiated phenotype observed in metastases is the result of an expansion of epitheloid cells 
or from actual reversion of EMT and a transition back to an epithelial phenotype from a 
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mesenchymal state. While studies suggest that both methods may be possible, few studies have 
directly shown that E-cadherin re-expression and MErT can be induced by the secondary organ 
microenvironment. 
Previous work in our laboratory has shown that prostate cancer cells re-express E-
cadherin when cultured with hepatocytes. While there are added levels of complexity to E-
cadherin regulation in breast cancer cells compared to prostate cancer cells, we aim to show that 
the liver microenvironment is capable of inducing E-cadherin re-expression in breast cancer 
cells. Furthermore, we aim to discern whether mesenchymal to epithelial reverting transition 
follows E-cadherin re-expression and whether these phenotypic transitions occur in breast cancer 
patients.  Finally, given that E-cadherin expression and cell adhesion have been shown to protect 
against chemotherapy- and detachment-induced cell death, we aim to show that such phenotypic 
plasticity has functional significance. In short, we hypothesize that metastatic breast 
carcinoma cells, as a result of E-cadherin re-expression, undergo a mesenchymal to 
epithelial transition in the liver to confer a survival advantage.  
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2.1 ABSTRACT 
Epithelial to mesenchymal transition (EMT) is an oft-studied mechanism for the initiation of 
metastasis. Despite a wealth of in vitro and in vivo studies, evidence of MErT in human 
specimens is difficult to document because clinically detectable metastases are typically past 
stage at which this transition is most likely evident. We obtained primary and metastatic tumors 
from breast and prostate cancer patients and evaluated expression of epithelial and mesenchymal 
markers by immunohistochemistry. The metastases exhibited increased expression of 
membranous E-cadherin compared to primary tumors, consistent with EMT at the primary site 
and MErT at the metastatic site. However, the re-emergence of the epithelial phenotype was only 
partial or incomplete. Expression of epithelial markers connexins 26 and/or 43 was also 
increased on the majority of metastases, particularly those to the brain. Despite the upregulation 
of epithelial markers in metastases, expression of mesenchymal markers vimentin and FSP1 was 
mostly unchanged. We also examined prostate metastases and found that while E-cadherin 
expression was increased compared to the primary lesion, the expression inversely correlated 
with size of the metastasis and distance from organ parenchyma. This suggests that a second 
EMT may occur in the ectopic site for tumor growth or to seed further metastases. In summary, 
we report increased expression of epithelial markers and persistence of mesenchymal markers 
consistent with a partial MErT that readily allows for a second EMT at the metastatic site. Our 
results suggest that cancer cells continue to display phenotypic plasticity beyond the EMT that 
initiates metastasis.  
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2.2 INTRODUCTION 
Recapitulation of the developmental process of epithelial to mesenchymal transition (EMT) has 
been proposed as a mechanism for enabling cancer cell invasion and dissemination. During 
cancer-associated EMT, loss of cell-cell adhesions via downregulation of E-cadherin allows for 
both physical detachment from the tumor mass and for external autocrine growth factor and 
internal signaling that activates cell migration (Wells et al., 2011). EMT in cancer progression 
and metastasis has been widely studied through in vitro cell culture and in vivo animal models of 
cancer progression. In addition, EMT has been visualized at the invasive front of primary 
carcinomas as individual cells or a group of cells migrating into the surrounding tissue (Wyckoff 
et al., 2000). However, the true extent of EMT in human cancer specimens is still open to debate, 
as is the role of EMT in metastatic seeding (Tarin et al., 2005; Wells et al., 2008; Wells et al., 
2011).  
Despite the strong clinical association between decreased expression of adhesion 
molecules and invasion and poor prognosis, metastases can present a well-differentiated, 
epithelial phenotype, bringing into question whether EMT is reversible. Others and we have 
proposed that a reverse EMT, or mesenchymal to epithelial reverting transition (MErT), occurs 
to enable metastatic colonization (Thiery, 2002; Chaffer et al., 2006; Hugo et al., 2007; Wells et 
al., 2008). Therefore, while induction of EMT through loss of E-cadherin promotes tumor 
invasion and dissemination, MErT through re-expression of epithelial genes and downregulation 
of mesenchymal genes may allow the metastatic cancer cell to complete the last steps of the 
metastatic process and to survive in the secondary organ. However, just as it has been difficult to 
capture EMT in vivo, there is also a dearth of histological evidence for MErT.  
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Opponents of cancer-associated EMT argue that there is a lack of convincing evidence in 
clinical samples that support the in vitro findings (Tarin et al., 2005). However, lack of evidence 
in clinical samples does not mean that an EMT or MErT has not occurred at some point in time, 
as pathological specimens are often end-stage observations. Unless clinically indicated, only a 
small percentage of metastases undergo surgical resection or biopsy, as systemic adjuvant 
endocrine, chemotherapy, or palliative radiation is more commonly used as therapy.  
Furthermore, specimens of metastases that are resected or that undergo biopsy originate from 
tumors of various stage and size (and ER/PR/HER2/neu status for breast cancer), making direct 
comparisons between patients difficult. Tumors often exhibit areas of poor differentiation with 
morphological changes, such as cell scattering and spindle-shaped cells that are distinct from the 
bulk of the tumor; however, pathologists do not routinely stain for markers of epithelial or 
mesenchymal phenotypes since diagnostic and prognostic value is absent. Despite these 
shortcomings, histological examination of epithelial and mesenchymal markers in primary 
tumors and their corresponding metastases is important to determine whether EMT and MErT 
occurs clinically, with implications for the development of new approaches to treat cancer.  
We have reported that E-cadherin-negative DU-145 prostate cancer cells can be induced 
to re-express E-cadherin by in vitro coculture with liver parenchymal cells (Yates et al., 2007). 
However, despite the findings of E-cadherin re-expression and an accompanying morphological 
change, it remained to be seen whether a full or partial mesenchymal to epithelial transition 
occurs. Thus, for the present study we evaluated the expression of mesenchymal and epithelial 
markers in a set of matched primary and metastatic tumor samples from breast cancer patients. 
We also focused on membranous expression of epithelial markers E-cadherin, β-catenin, 
connexin 26, and connexin43 as an indicator of normal function. Expression of epithelial 
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markers was increased in metastases while expression of mesenchymal markers fibroblast-
specific protein (FSP1) and vimentin was variably changed, suggesting a partial MErT. In 
addition, we corroborated our results in a set of unmatched primary and metastatic prostate 
cancer samples and found that E-cadherin expression decreased with both increasing metastatic 
tumor size and distance from secondary organ parenchyma. This observation suggests that MErT 
is also reversible and helps to answer the question of whether metastases generate other 
metastases or if all metastases arise from the primary tumor. 
2.3 RESULTS 
2.3.1 Breast cancer metastases exhibit increased levels of localization of adherens junction 
components to the membrane 
A few studies have compared E-cadherin expression in the primary tumor and distant metastases 
(Bukholm et al., 2000; Kowalski et al., 2003). However, the cases analyzed in these studies 
included metastases to lymph nodes or uncommon sites of breast cancer metastasis. To conduct 
our own survey focusing on metastases to the most common sites, we obtained specimens of 
primary tumors and the corresponding metastases from 16 patients with infiltrating ductal 
carcinoma. Metastatic sites from which tissue was obtained included the lung (12 cases), liver 
(3), and brain (6). Besides bone, these comprise the most common sites of breast cancer 
metastases. Both primary tumor and metastases were immunostained for E-cadherin. E-cadherin 
positive cells were counted based on high intensity membrane staining. Percentage of E-cadherin 
positivity was calculated as the number of E-cadherin-positive cells over the total number of 
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cancer cells in each field. We quantified only positive membranous staining, as functional E-
cadherin that both participates in intercellular adhesion and sequestration of the catenins is only 
localized at the membrane. Overall, 17/20 (85%) cases showed increased membranous E-
cadherin expression in the metastases compared to the primary tumors (Figure 4a), with this 
being consistent across the various sites; 2/2 (100%) of liver metastases, 5/6 (83%) of brain 
metastases, and 10/12 (83%) of lung metastases exhibited increased E-cadherin expression. 
Localization of β-catenin at the cell membrane is a critical suppressor of cancer cell 
migration and invasion as it forms part of a stable adherens junction (Brabletz et al., 2001; Wong 
and Gumbiner, 2003). We therefore evaluated primary and metastastic tumors for membranous 
β-catenin expression (Figure 4b). Overall, 9/20 (45%) of metastases exhibited increased 
expression of membranous β-catenin; 7/12 (58%) of lung metastases, 1/2 (50%) of liver 
metastases, and 1/6 (17%) in brain metastases. When positive β-catenin expression was 
quantified as including both membranous and cytoplasmic expression, increased β-catenin was 
evident in metastases compared to primary tumors, in 9/12 (75%) of lung metastases, 2/2 (100%) 
of liver metastases, and 1/6 (17%) of brain metastases (data not shown). Due to the activation of 
the downstream Wnt pathway, nuclear localization of β-catenin is most commonly associated 
with the invasive phenotype; therefore β-catenin involvement in an epithelial phenotype may be 
best quantified by membranous and cytoplasmic localization. 
 
 
A.1.2  
 50 
 
 
Figure 4. Breast cancer metastases exhibit increased localization of adherens junctions 
components to the membrane. A) Quantification of membrane-bound E-cadherin in breast 
cancer primary tumors and metastases. Representative images of a primary tumor 
exhibiting cytoplasmic or absent E-cadherin and the paired lung metastasis with 
membranous E-cadherin expression. B) Quantification of membranous β-catenin in 
primary and metastatic tumors. Images from a case that exhibited increased membranous 
β-catenin staining in a metastasis to the lung. Organ sites of metastases are color-coded: 
lung (blue), red (liver), and brain (green). Size bar in the photomicrographs is 25 microns. 
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2.3.2 Expression of gap junction proteins is increased in breast cancer metastases to the 
brain 
While adherens junctions facilitate intercellular adhesion, gap junctions mediate intercellular 
communication by the exchange of small molecules and ions through a membrane-spanning pore 
composed of connexins. In the breast, connexin 26 (Cx26) is expressed by luminal cells while 
connexin 43 (Cx43) is expressed by myoepithelial cells (Monaghan et al., 1996).  Loss of Cx26 
and Cx43 correlates with tumor progression in breast and colorectal cancer and over-expression 
of Cx43 reduces breast cancer metastasis (Kanczuga-Koda et al., 2005; McLachlan et al., 2006; 
Li et al., 2008). Furthermore, just as re-expression of E-cadherin has been observed in 
metastases, increased expression of Cx26, Cx43, and Cx32 has been found in breast cancer 
lymph node metastases, suggesting that re-expression of gap junctions could also contribute to a 
MErT (Kanczuga-Koda et al., 2006; Kanczuga-Koda et al., 2007). We therefore surveyed the 
expression of membranous Cx26 and Cx43 in primary and metastatic tumors. For Cx26, 10/19 
(53%) metastases showed increased membranous expression: 5/11 (45%) of lung metastases, 1/2 
(50%) of liver metastases, and 4/6 (66%) of brain metastases (Figure 5a). Increased expression of 
membranous Cx43 expression was observed in 55% (11/20) of all metastases, specifically in 
4/12 (33%) of lung metastases, 1/2 (50%) of liver metastases, and 6/6 (100%) of brain 
metastases (Figure 5b). For the most part, the two connexins changed or stayed similar in parallel 
fashion within each metastasis. While there was no correlation in metastases to lung or liver, 
both Cx26 and Cx43 expression were strikingly increased in metastases to the brain.  
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Figure 5. Expression of gap junctional proteins is increased in breast cancer metastases to 
the brain. Quantification of membranous Cx26 (A) and Cx43 (B) staining in primary and 
metastatic tumors. Shown are representative images of connexin staining in primary tumors and 
brain metastases. Organ sites of metastases are color-coded: lung (blue), red (liver), and brain 
(green). Size bar in the photomicrographs is 25 microns. 
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2.3.3 Persistence of mesenchymal markers in metastases suggests a partial mesenchymal 
to epithelial reverting transition 
To determine if the increase in epithelial markers signified the occurrence of a full MErT, which 
includes a loss or decrease in expression of mesenchymal markers in metastases, we next 
evaluated the expression of FSP1 and vimentin. FSP1 is considered one of the few truly 
fibroblast-specific markers and is commonly used as an early marker of EMT (Okada et al., 
1997; Trimboli et al., 2008). Vimentin is also a widely accepted marker of the mesenchymal 
phenotype in EMT. During EMT, cells undergo a shift from using cytokeratin intermediate 
filaments to vimentin intermediate filaments, which are involved in the changes in adhesion and 
motility (Mendez et al., 2010; Vuoriluoto et al., 2010). Immunohistochemistry revealed that 
overall only 9/19 (47%) of metastases showed decreased expression of FSP1: 4/11 (36%) of lung 
metastases, 1/2 (50%) of liver metastases, and 4/6 (66%) of brain metastases (Figure 6a). 
Similarly, 13/20 (65%) of metastases exhibited decreased expression of vimentin: 7/12 (64%) of 
lung metastases, 2/2 (100%) of liver metastases and 4/6 (66%) of brain metastases (Figure 6b). 
For metastases that did display a decrease in expression of FSP1 or vimentin, the degree of 
change was small relative to the change observed in E-cadherin. The lack of a dramatic 
downregulation of mesenchymal markers suggests that only a partial MErT occurs during 
metastatic colonization.  
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Figure 6. Mesenchymal markers persist in metastases, suggesting only a partial MErT. 
Quantification of immunostaining for mesenchymal markers FSP1 (A) and vimentin (B). Images 
of FSP1 and vimentin staining in primary tumors and metastases. Organ sites of metastases are 
color-coded: lung (blue), red (liver), and brain (green). Size bar in the photomicrographs is 25 
microns. 
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2.3.4 Size of metastasis and distance from organ parenchyma affects E-cadherin 
expression 
To extend our findings beyond breast cancer, we obtained a number of unmatched prostate 
carcinoma primary tumors and metastases. Organ sites of metastases included liver, lung, kidney, 
and thyroid. Primary and metastatic tumors were immunostained for E-cadherin and staining 
intensity was quantified with ImageJ. Metastases exhibited increased staining of E-cadherin 
compared to primary tumors (p< .05), suggesting that E-cadherin re-expression can occur in 
other cancers besides breast carcinoma (Figure 7a). Due to a shortage of specimens, staining for 
other epithelial and mesenchymal markers was not performed.  
Several of the metastatic specimens from individual patients contained multiple foci of 
different sizes. The metastatic foci within one patient sample were divided into three categories 
based on size: less than 50µm in diameter (small), between 50µm and 100µm in diameter 
(medium), and larger than 100µm in diameter (large) (Figure 7b). The staining intensity of E-
cadherin was quantified for each individual focus. Interestingly, E-cadherin expression inversely 
correlated with tumor size, with increased E-cadherin expression in small metastases compared 
to large (p< .001) (Figure 7c), suggesting that the partial MErT that allows for metastatic 
colonization is transient and reversible like the EMT that enables metastatic dissemination.   
Additionally, the distribution of E-cadherin expression within metastases did not appear 
to be random. In many cases, E-cadherin expression was increased at the edges of contact with 
organ parenchymal cells. For example, a liver metastasis demonstrating increased expression at 
the hepatocyte-cancer cell interface and decreased expression centrally is shown, suggesting that 
E-cadherin is directly regulated by hepatocyte interactions (Figure 8a). Quantification of staining 
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intensity confirmed an increase in E-cadherin expression in the area outlined by the solid inset 
compared to the area outlined by the dashed inset located further away from hepatocytes (Figure 
8b).  
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Figure 7. E-cadherin expression in prostate cancer metastases is inversely correlated with 
size of metastasis. A) Quantification and representative images of prostate cancer primary and 
metastatic tumors immunostained for E-cadherin. *p < 0.05 B) Images of metastatic tumors 
stained for E-cadherin as categorized by size: small (less than 50µm in diameter), medium 
(between 50µm and 100µm) and large (bigger than 100µm). C) Quantification of E-cadherin 
expression in different sized prostate cancer metastases. +p<0.001 *p<0.05. Size bar in the 
photomicrographs is 25 microns. 
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Figure 8. E-cadherin expression decreases with increased distance from organ 
parenchyma. A) Heterogeneous expression of E-cadherin in the center (dashed inset) versus 
edge (solid inset) of a liver metastasis. “C” denotes tumor and “H” denotes hepatocytes. B) 
Quantification of E-cadherin staining in the center and edge of the liver metastasis.  
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Table 1. Summary of epithelial and mesenchymal marker expression data. 
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2.4 DISCUSSION 
One of the major limitations of studying metastasis in vivo is that studies involving animal 
models and clinical samples are end-stage time points that only provide a snapshot of the 
metastatic cascade at the point of tissue harvest. Although intravital imaging and use of 
organotypic bioreactors has improved the ability to visualize metastasis at various stages, the 
phenotypic plasticity exhibited during EMT and MErT is nonetheless difficult to capture (Yates 
et al., 2007; Giampieri et al., 2010; Stoletov et al., 2010). Evidence of EMT and MErT in clinical 
specimens is rare and has been used as an argument that cancer-associated EMT does not occur 
during the course of disease. Using matched primary and metastatic tumors, we have examined 
expression of epithelial and mesenchymal markers in specimens obtained from human breast 
cancer patients. Our results show that the occurrence of cancer-associated EMT and MErT is 
possible. Loss of expression of E-cadherin is widely considered to be a hallmark of EMT. If 
metastases are the result of clonal expansion of a primary tumor cell that has undergone EMT, 
then one would expect metastases to be E-cadherin-negative unless this phenotype is plastic. The 
finding of E-cadherin-positive metastases suggests that non-EMT cells can establish metastases 
or that MErT at the metastatic site can occur. 
Paget’s “seed and soil” hypothesis posits that cancer cells only survive and grow in 
appropriate environments; the reversible phenotypic plasticity of cancer cells during EMT and 
MErT is therefore one way in which cancer cells adapt to the foreign soil of ectopic organ 
microenvironments. Expression of adhesion molecules is necessary to complete the final steps of 
the metastatic cascade including intravasation and colonization (Glinskii et al., 2005). We also 
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included analysis of E-cadherin binding partner β-catenin, gap junction molecules Cx26 and 
Cx43 and mesenchymal markers FSP1 and vimentin to discern whether a full or partial MErT 
occurs (summarized in Table 1). We limited our quantification of E-cadherin, β-catenin, Cx26, 
and Cx43 to expression localized to the membrane to account for proteins functioning in the 
epithelial phenotype, as dysfunctional proteins are commonly dislocated in the cytoplasm or 
nucleus during tumor progression. Increased expression of membranous E-cadherin was 
observed in metastases compared to primaries, across all organ sites of metastases. While we 
expected these results in metastases to lung and to liver where E-cadherin is expressed by 
pneumocytes and hepatocytes, it was surprising that 83% of metastases to the brain also 
exhibited increased E-cadherin expression. Breast cancer cells that metastasize to bone have 
been shown to express OB-cadherin, the cadherin expressed by osteocytes, so it was expected 
that metastases would exhibit increased expression of the adhesion molecule native to the ectopic 
organ (Li et al., 2008; Huang et al., 2010). Thus, increased E-cadherin expression was not 
expected in metastases to the brain, which primarily expresses N-cadherin. When we queried N-
cadherin expression in primary and metastastic tumors, only 2/5 brain metastases exhibited 
increased N-cadherin expression (data not shown). 
It is not surprising that an overall corresponding increase in membranous β-catenin was 
not observed in metastases, as in all specimens the percentage of cells expressing β-catenin was 
higher than the E-cadherin-expressing cells. Thus, there was limited amount of increase that 
could be noted with β-catenin. This high level could be due to β-catenin binding to other 
cadherins. E-cadherin is not the only molecule that sequesters β-catenin, as the cytoplasmic 
domains are conserved among the type I classical cadherins. To test this, samples were also 
stained for N-cadherin (data not shown). While there was no consistent pattern of N-cadherin 
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expression between primary tumors and metastases, high N-cadherin expression in the primary 
tumor was observed in many cases that exhibited no change or decreased localized β-catenin 
expression in metastases.  
We also evaluated expression of gap junction molecules as another measure of epithelial 
gene expression in MErT. Cx26 and Cx43 are disparately expressed in the breast – luminal cells 
express Cx26 while myoepithelial cells express Cx43 (Monaghan et al., 1996). Although the 
luminal and basal breast cancer subtypes arise from these two different cell types, there was no 
association between connexin expression and ER/PR/Her2 status, and therefore breast cancer 
subtype. Overall, metastases exhibited increased expression of Cx26 and Cx43 compared to the 
primary tumors. This was most striking in brain metastases, where 66% of brain metastases 
demonstrated increased Cx26 expression and 100% showed increased Cx43 expression. In the 
brain, Cx26 and Cx43 are expressed by astrocytes, which suggests that gap junctions and not 
adherens junctions may be the driving force behind brain metastases. We have hypothesized that 
MErT in metastatic colonization serves to protect the metastatic cancer cell from inflammatory 
or chemotherapeutic insult (Wells et al., 2008). Recent in vitro work by the Fidler group supports 
both our findings of increased connexin expression in brain metastases and also the theory that 
this re-expression confers a survival advantage. Melanoma or breast cancer cells cultured with 
astrocytes demonstrated reduced chemosensitivity, which was mediated by expression of 
connexins (Langley et al., 2009; Fidler et al., 2010; Lin et al., 2010). 
When immunostaining was performed for the mesenchymal markers FSP1 and vimentin, 
expression of these markers in metastases was either unchanged or slightly decreased, suggesting 
only a partial MErT. In addition, tumors are typically surrounded by reactive fibrosis, or 
desmoplasia, as well as normal stromal cells that stain positively for mesenchymal markers. 
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Therefore, the possibility of false positives is high. Ideally, dual staining for breast cancer-
specific and mesenchymal markers would overcome this problem; however, a reliable breast 
cancer-specific marker does not exist. Cell-cell adhesion and cell motility are usually viewed as 
attributes of opposing sides of the epithelial and mesenchymal phenotypic spectrum. However, 
partial EMT and MErT in which cells maintain some level of both is not an unusual 
phenomenon, as many examples of intermediate phenotypes can be found throughout cancer 
progression. During invasion, tumors have been shown to invade the ECM collectively as strands 
of cancer cells that maintain expression of adhesion molecules (Friedl and Gilmour, 2009). 
Similarly, during extravasation, cancer cells re-express molecules that permit adhesion to 
endothelial cells yet still maintain the ability for transendothelial migration (Gout et al., 2008; 
Schmidmaier and Baumann, 2008).  
Finally, we found that E-cadherin expression decreases with increasing metastatic tumor 
size, suggesting that just as EMT is reversible, so is MErT. These data support earlier 
experimental evidence that the EMT that allows for escape from the primary lesion is not fixed 
but can be reverted during metastatic seeding (Yates et al., 2007; Chao et al., 2010; Wells et al., 
2011). However, pathological examination of large metastases removed for palliative or 
diagnostic needs often present de-differentiated cells reminiscent of the original EMT, which 
superficially appears at odds with our model of MErT. These data can be reconciled by our 
analysis of the prostate carcinoma micrometastases. In evaluating expression of E-cadherin based 
on metastasis size, we found the larger metastases (all still microscopic clinically) were less 
likely to express E-cadherin at the membrane, implying a re-emergence of EMT as with tumor 
growth. Similar changes were observed in a study of claudin expression in primary tumors and 
liver metastases. Several of the larger liver lesions exhibited re-expression of claudin 4, 
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compared to earlier, smaller tumors (Erin et al., 2009). In addition, re-expression of other 
adhesion molecules such as claudin 7 and γ-catenin have been demonstrated in lymph node 
metastases (Park et al., 2007). E-cadherin expression was also increased at the edge of 
metastases compared to the center. This suggests that soluble or ECM-derived factors or physical 
interaction with the secondary organ may be necessary to maintain MErT.  Thus, the phenotypic 
plasticity of carcinomas allows for continual repositioning of the tumor cell to provide a survival 
or dissemination advantage. 
The reversibility of MErT at the secondary site alludes to the question of whether all 
metastases necessarily arise from the primary tumor or whether metastases can give rise to 
metastases. An autopsy study of breast cancer patients found that the frequency of metastases to 
non-common sites is lower when metastases to the lung, liver, or bone are not already present 
(Viadana et al., 1973). In a mouse model, systemic metastases arise in mice with large lung 
metastases in the absence of the primary tumor (Alterman et al., 1985; Stackpole, 1990). One 
explanation is dormant cells were already seeded in the lung prior to primary tumor removal, but 
parabiosis experiments reveal that the non-tumor bearing partner develop metastases (Hoover 
and Ketcham, 1975). Despite these observations, the mechanism by which these secondary 
metastases occur is still unknown. Here we suggest that EMT may occur following MErT in the 
metastatic site to engender these secondary metastases. Ultimately, the persistence of 
mesenchymal characteristics in MErT, despite the re-expression of epithelial genes and adhesion 
molecules, enables metastatic cancer cells to adeptly adapt to changing environments – from 
primary tumor to secondary organ and beyond. 
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2.5 MATERIALS AND METHODS 
2.5.1 Immunohistochemistry 
All studies were performed on de-identified specimens obtained during clinically-indicated 
procedures; these were deemed to be exempted (4e) from human studies by the University of 
Pittsburgh Institutional Review Board. Paraffin-embedded patient samples, excess to clinical 
need, were obtained from the University of Pittsburgh Tissue Banks, primarily coming from 
Magee Womens Hospital of UPMC and UPMC Shadyside Hospital, under informed consent of 
patients undergoing diagnostic and therapeutic procedures.  
Samples were deparaffinized for 1 hour at 55°C and hydrated. Sections underwent 
antigen retrieval in citrate buffer, pH 6.0 (Dako) followed by 10 minutes of peroxidase blocking 
in 0.3% hydrogen peroxide and 10 minutes of protein blocking in 5% goat serum. Samples were 
then incubated with primary antibodies for one hour: E-cadherin (Cell Signaling), β-catenin 
(abcam), connexin 26 (abcam), connexin 43 (abcam), FSP1/S100A4 (abcam), and vimentin 
(abcam) followed by biotin-conjugated secondary antibody incubation for one hour (Jackson 
Laboratories). After washing several times, slides were then incubated with Streptavidin-
Peroxidase (Vectastain) followed by chromagen substrate (Vector Laboratories). The reaction 
was quenched once DAB staining was visualized. Lastly, samples were counterstained with 
Mayer's hematoxylin. Staining using only secondary antibody served as a negative control and 
adjacent normal tissue served as an internal positive control. Images of three randomly selected 
microscope fields of each sample were taken and the percentage of cancer cells with positive 
staining was quantified as the number of positive cells over the total number of cancer cells in 
that image. Microscope fields shown were selected to account for the heterogeneity of each 
A.1.2  
 66 
sample. For the unmatched prostate cancer samples, mean density of E-cadherin staining was 
quantified using the Color Deconvolution plug-in for ImageJ software.   
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3.1 ABSTRACT 
Epithelial to mesenchymal transition (EMT), implicated as a mechanism for tumor 
dissemination, is marked by loss of E-cadherin and induction of cell motility. Epigenetic 
methylation of the promoter leads to dynamic regulation of E-cadherin expression that is open to 
modulation by the microenvironment. We have previously shown increased E-cadherin 
expression along with persistent expression of mesenchymal markers in metastases compared to 
the primary tumor, indicating a partial MErT at metastatic sites. These observations led to the 
question of whether the positive metastatic foci arose from expansion of E-cadherin-positive 
cells or from MErT of originally E-cadherin-negative disseminated cells. Thus, we aimed to 
determine if mesenchymal-like MDA-MB-231 breast cancer cells could undergo a MErT 
through the re-expression of E-cadherin. Ectopic expression of full-length E-cadherin in MDA-
MB-231 cells resulted in a morphological and functional reversion of the epithelial phenotype, 
with even just the cytosolic domain of E-cadherin yielding a partial phenotype. Introduction of 
MDA-MB-231 cells or primary explants into a secondary organ environment simulated by a 
hepatocyte coculture system induced E-cadherin re-expression through passive loss of 
methylation of the promoter. Furthermore, detection of E-cadherin-positive metastatic foci 
following the spontaneous metastasis of MDA-MB-231 cells injected into the mammary fat pad 
of mice suggests that this re-expression is functional. Our clinical observations and experimental 
data indicate that the secondary organ microenvironment can induce the re-expression of E-
cadherin and consequently MErT. This phenotypic change is reflected in altered cell behavior 
and thus may be a critical step in cell survival at metastatic sites.  
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3.2 INTRODUCTION 
Breast cancer is the most frequently diagnosed cancer in women, and it is the second leading 
cause of cancer death in women of all ages (Punglia et al., 2007).  Intraductal carcinoma, which 
originates from the epithelial cells lining the mammary ducts, is the most common type of breast 
cancer. Metastasis occurs via a series of sequential steps, during which the cells acquire an 
mesenchymal-like phenotype, become motile, disseminate, and colonize distant sites of the body, 
which in breast cancer are most commonly liver, lung, bone, and brain. The stages of this 
transformation are similar to the stages of the developmental process epithelial to mesenchymal 
transition (EMT) (Lee et al., 2006). Much of the current literature supports the idea that EMT is 
the key mechanism by which tumor cells gain invasive and metastatic ability, as EMT enables 
separation of individual cells from the primary tumor mass as well as promotes migration (Tse 
and Kalluri, 2007; Trimboli et al., 2008). After undergoing EMT, thereby enabling access to 
hematogenous or lymphatic routes of dissemination, tumor cells extravasate into secondary 
organs and establish micrometastases. We have hypothesized that EMT is reversible and that a 
reversion back towards the epithelial phenotype may occur at the secondary metastatic site 
(MErT). A similar reversion occurs in development when neural crest cells undergo a transient 
EMT followed by a permanent MET to generate tissues such as kidney epithelia (Hugo et al., 
2007). A few studies have charted switches between EMT and MET phenotypes throughout 
malignant progression such as in colorectal cancer (Brabletz et al., 2001), bladder cancer 
(Chaffer et al., 2006), and ovarian cancer (Hudson et al., 2008). The phenotypic plasticity 
observed in these cases is unlikely to be generated by the acquisition of permanent genetic 
insults, suggesting that the microenvironment is capable of inducing epigenetic changes.  
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Numerous extracellular signals such as growth factors and stromal signals, and stressors 
such as hypoxia and ROS have been implicated in the induction of EMT (Polyak and Weinberg, 
2009). However, at the core of the transition between an epithelial and a mesenchymal 
phenotype is the loss of E-cadherin expression. E-cadherin is a classical member of the cadherin 
family, whose extracellular domain facilitates homotypic intercellular adhesions while the 
cytosolic tail assembles catenins and other signaling and scaffolding molecules at the membrane 
to link to the actin cytoskeleton (Hirano et al., 1987; Takeichi, 1991). E-cadherin-mediated cell-
cell adhesions limit cell motility and establish apical-basal polarity. The loss of E-cadherin 
expression and disassembly of E-cadherin adhesion plaques on the cell surface enables tumor 
cells to disengage from the primary mass and move to conduits of dissemination. This duality of 
functionalities—intercellular cohesion and regulation of intracellular signaling cascades—
suggests that E-cadherin impacts multiple aspects of epithelial homeostasis. 
Thus, E-cadherin expression is intimately connected to a cell’s degree of epitheliality – in 
both morphology and migratory and invasive abilities. In cancer pathogenesis, E-cadherin 
expression is dynamically regulated via epigenetic mechanisms, specifically methylation of the 
promoter, providing tumor cells the plasticity to switch between EMT and MErT depending on 
the microenvironment (Graff et al., 2000). Interestingly, metastases often resemble the epithelial-
like phenotype of the primary tumor rather than the mesenchymal phenotype observed at the 
invasive front. Several pathological studies, including one described previously in Section 2.0, 
have observed increased E-cadherin expression in metastases compared to aberrant or loss of 
expression in the primary tumors, further challenging the notion that EMT is irreversible and 
suggesting that E-cadherin may be involved in MErT at the metastatic site (Kowalski et al., 
2003; Yates et al., 2007). However, one limitation of these pathological studies is that it is 
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impossible to determine whether these E-cadherin-positive metastases result from the rare escape 
and expansion of epithelial carcinoma cells, such as in the cell cooperativity model, or whether 
they arise from a mesenchymal-like cell that has undergone a phenotypic reversion back to a 
more differentiated phenotype, as we hypothesize. 
Therefore, we aimed to experimentally determine whether it was possible for the 
mesenchymal-like MDA-MB-231 breast cancer cells to undergo an MErT through the re-
expression of E-cadherin, either through exogenous introduction or through induction by the 
microenvironment. Ectopic expression of E-cadherin in MDA-MB-231 cells resulted in a 
reversion back to some degree of the epithelial phenotype, particularly with respect to 
morphology and functional suppression of migration and invasion. Furthermore, introduction of 
breast cancer cells and primary explants into a secondary organ environment led to the passive 
loss of methylation of the E-cadherin promoter and re-expression of this cell-cell adhesion 
molecule, demonstrating a mechanism for this reversion of EMT. In vivo experiments in mice 
revealed similar results in lung metastases, suggesting that re-expression of E-cadherin may be a 
critical step in metastatic colonization of not only the liver but lung as well.  
3.3 RESULTS 
3.3.1 Ectopic expression of E-cadherin partly reverts breast cancer cells towards an 
epithelial phenotype 
The finding of more prevalent E-cadherin expression in metastases compared to the paired 
primary tumors led to the question of whether the positive metastatic foci arose from expansion 
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of E-cadherin-positive cells or from MErT of originally E-cadherin-negative cells. Thus, we 
aimed to determine whether it was possible for the mesenchymal-like MDA-MB-231 breast 
cancer cells to become more epithelial following expression of E-cadherin. In MDA-MB-231 
cells, E-cadherin expression is suppressed by methylation of the promoter. We stably transfected 
full-length E-cadherin driven by a CMV promoter and generated single cell clones (231-Ecad). 
In addition, because the possibility of intermediate EMT/MErT phenotypes has been proposed, 
we also stably transfected MDA-MB-231 cells with a construct composed of the intracellular and 
transmembrane domains of E-cadherin coupled to the class I major histocompatibility complex 
antigen (H-2kd) extracellular domain (231-H2kd). Such a construct was originally used to 
examine the contribution of internal E-cadherin signaling in the absence of E-cadherin-mediated 
intercellular interactions (Vizirianakis et al., 2002; Fedor-Chaiken et al., 2003). We postulated 
that expressing only the cytosolic tail of E-cadherin would allow for a partial MErT through the 
intracellular sequestration of adherens junction components and other effector proteins that is 
observed in epithelial cells but absent in mesenchymal cells. Immunoblot and 
immunofluorescence confirmed the exogenous expression of E-cadherin and E-cadherin-H2kd in 
MDA-MB-231 cells (Figures 9 and 10). 231-Ecad and 231-H2kd mutants display colocalization 
with the catenins at the membrane (Figure 10). E-cadherin expressing MCF7 breast cancer cells 
were used as a positive control. 231-Ecad cells exhibited cobblestone or cell-cell clustered 
morphology and formed cell contacts, which were not observed in control transfected MDA-
MB-231 cells. 231-H2kd cells demonstrated a more flattened morphology that did not fully 
resemble either epithelial or mesenchymal phenotypes (Figure 9). As expected, 231-H2kd cells 
did not form cell-cell contacts. It is important to note that this culture was performed at low cell 
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density, so that cells were limited in establishing cell-cell connections. Thus, outside-in signaling 
mediated by E-cadherin was not necessary for the morphology change.  
We next analyzed the expression of epithelial and mesenchymal markers in the various 
cell lines to monitor the penetrance of the epithelial/mesenchymal phenotypes. We evaluated the 
expression of a spectrum of cytokeratins including cytokeratin-18 (CK-18), the primary 
intermediate filament present in epithelial cells. Expression of vimentin, smooth muscle actin, 
and fibronectin were used as markers of the mesenchymal phenotype. Loss of cytokeratins and 
increased expression of vimentin, smooth muscle actin, or fibronectin have been shown to occur 
concurrently with EMT in adenocarcinomas (Gotzmann et al., 2004; Kokkinos et al., 2007). The 
survey of these epithelial and mesenchymal markers revealed that 231-Ecad cells demonstrated 
decreased expression of smooth muscle actin, fibronectin, and vimentin and increased expression 
of cytokeratins (Figure 11a). Upregulation of N-cadherin has been observed in EMT, but because 
N-cadherin is not expressed in MDA-MB-231 cells this mesenchymal marker was not tested. 
231-Ecad cells displayed increased cytokeratin-18 and decreased vimentin expression as assayed 
by immunofluorescence (Figure 11b). As epithelial and mesenchymal cells also differ in their 
cytosketelal architecture, phalloidin was used to visualize the actin cytoskeleton.  Expression of 
the entire E-cadherin molecule (231-Ecad) provided a more epithelial-like reticular actin 
filament meshwork. The persistence of mesenchymal markers and failure to fully express 
epithelial markers in 231-Ecad cells compared to the epithelial MCF7 cells suggests that MDA-
MB-231 cells transfected with E-cadherin (either wild-type or cytosolic tail) still maintain some 
aspects of mesenchymal phenotype.  
Mesenchymal and epithelial phenotypes also confer functional behaviors on tumor cells. 
We therefore tested the two key properties related to tumor escape enabled by EMT: migration 
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and invasion. After an in vitro scratch assay, which measures migration, we observed that 
expression of full-length or the cytosolic region of E-cadherin resulted in suppressed migration 
almost down to low levels noted for the epithelial MCF7 cancer line (Figure 12a).  Similar trends 
were observed in the Matrigel invasion assay, which integrates motility with other properties 
such as matrix remodeling to better recreate the movement through bioactive matrices that 
defines tumor invasion. The invasive ability of both 231-Ecad and 231-H2kd cells was 
suppressed compared to MDA-MB-231 cells (Figure 12b). That suppression of migration and 
invasiveness were observed in 231-H2kd cells in the absence of changes in expression in the 
marker genes suggests that these functional behaviors may be independent of a mesenchymal to 
epithelial transition. While 231-H2kd cells may be similar to wild-type 231 cells in terms of 
mesenchymal and epithelial gene expression, β-catenin localization differed (Figure 10a). While 
231 cells exhibit cytoplasmic distribution of β-catenin, 231-H2kd cells localize α-catenin, β-
catenin, and p120 to the cell membrane as do the epithelial counterparts 231-Ecad and MCF7 
cells. As reported by other groups, this alteration alone is sufficient to account for the invasion 
suppressor phenotype (Wong and Gumbiner, 2003). 
In summary, these results indicate that expression of exogenous E-cadherin (wild-type or 
cytosolic tail) in MDA-MB-231 cells results in a morphological shift toward the epithelial end of 
the spectrum. The expression of both epithelial and mesenchymal markers in 231-Ecad and 231-
H2kd cells demonstrate that these cells may not have undergone a complete MErT, but the 
migration and invasion assay data suggest that expression of the full-length and cytosolic 
domains of E-cadherin are sufficient to induce a more epithelial-like phenotype in terms of cell 
motility and invasiveness. Furthermore, suppression of invasion and migration in 231-H2kd was 
comparable to the suppression in 231-Ecad cells, indicating that changes to the localization of 
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key signaling proteins during the mesenchymal to epithelial transition can have profound effects 
in mitigating the mesenchymal nature of an invasive cell. 
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Figure 9. Expression of full-length and cytosolic E-cadherin in MDA-MB-231 cells alter 
morphology A) Cell morphology as examined by phase contrast microscopy (left column) and 
E-cadherin expression (red) as detected by immunofluorescence (right column) B) Immunblot 
analysis illustrates ectopic expression of E-cadherin in 231-Ecad cells.  
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Figure 10. 231-H2kd mutants localize β-catenin to the membrane A) H2kd, left panel, green; 
α-, β- or p120-catenin, middle panel, red; merge, right panel, yellow. B) Transfected MDA-231 
cells express the H2kd fragment.  When 231-H2kd whole cell lysates are probed with an H2kd 
antibody and immunoprecipitated, both beta- and p120 catenins coimmunoprecipitate as 
determined by immunoblot. 
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Figure 11. Expression of epithelial and mesenchymal markers in E-cadherin mutants A) 
Immunblot of epithelial and mesenchymal marker expression in the E-cadherin mutants. B) 
Immunofluorescence of vimentin, cytokeratin-18 and actin cytoskeleton (rhodamine phalloidin). 
Shown are representative of at least three different assessments using one of two independent 
clones of each cell variant.  
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Figure 12. Expression of full-length and cytosolic E-cadherin suppresses migration and 
invasion A) Cell migration was analyzed using a scratch assay. Scratch closure was measured 
over a period of 24 hours and the fraction closure was quantified by Metamorph software (n=3). 
B) Invasion was measured using a Matrigel invasion assay in which cells were allowed to 
migrate through a Matrigel-coated transwell insert for a period of 24 hours. N = 3 in triplicate; 
mean ± s.e.m. Results shown are representative of one of two independent clones of each mutant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.1.2  
 80 
3.3.2 E-cadherin expression is induced by a secondary organ microenvironment 
Our previous results demonstrating E-cadherin expression in metastases suggested that a 
reversion to a more epithelial phenotype is possible at the metastatic site. We therefore 
hypothesized that a secondary organ microenvironment could induce re-expression of E-
cadherin. To test this hypothesis, we cultured MDA-MB-231 cells with rat hepatocytes, as the 
liver is one of the main organs to which breast cancer cells metastasize. After 6 days of culture, 
expression of E-cadherin was detected using a human specific E-cadherin antibody (Figure 13a). 
Control experiments confirmed that the human-specific antibody did not cross-react with E-
cadherin of rat origin, indicating that the E-cadherin was re-expressed by MDA-MB-231 cells 
(data not shown). Expression was also detected by flow cytometry (Figure 13b). Side and 
forward scatter as well as hepatocyte-specific autofluorescence gating were used to exclude the 
hepatocyte population. Flow cytometry analysis of MDA-MB-231 cells after 6 days of co-culture 
with hepatocytes formed a bimodal distribution, with 22% of cells forming a distinct population 
of E-cadherin positive cells. Culture of MDA-MB-231 cells in hepatocyte growth media alone 
did not result in re-expression, indicating that the re-expression is driven by hepatocytes (Figure 
13c). Increased expression of E-cadherin mRNA was also detected by qRT-PCR (Figure 13d). 
After 6 days of culture with hepatocytes, MDA-MB-231 exhibited levels of E-cadherin transcript 
comparable to E-cadherin-positive MCF7 cells, while MDA-MB-231 cells cultured in the 
absence of hepatocytes presented undetectable mRNA levels.  The fact that the E-cadherin 
mRNA level appears to be similar to that in MCF-7 cells despite lower protein levels is likely 
due to autocrine EGFR signaling driving E-cadherin internalization and degradation. 
To prevent re-expression of E-cadherin in coculture and to validate that the changes 
noted were from E-cadherin and not another undefined co-expressed protein, we stably 
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transfected MDA-MB-231 cells with an E-cadherin shRNA plasmid construct and generated 
single cell clones (231-shEcad). In addition, breast carcinoma cells were RFP-labeled to more 
easily discriminate cancer cells from hepatocytes in coculture. While MDA-MB-231, 231-H2kd, 
and 231-Ecad cells reverted to an epithelial clustered morphology following hepatocyte 
coculture, 231-shEcad cells remained fibroblastic (Figure 14). This reversion to an epithelial 
morphology was not observed when 231 cells were cocultured with primary fibroblasts for 6 
days (Figure 15). Immunofluorescence confirmed that the shRNA construct prevented re-
expression of E-cadherin (Figure 16, left column). To evaluate whether MErT occurs following 
E-cadherin re-expression, cocultures were immunostained for the mesenchymal marker 
vimentin. Just as expression of mesenchymal markers persisted in 231-Ecad cells, E-cadherin re-
expression in coculture did not completely suppress expression of vimentin (Figure 16, right 
column). However, vimentin expression appeared more heterogeneous, with some cells 
expressing more than others. It is important to note that compared to 231-Ecad cells where E-
cadherin was exogenously expressed, there may be other unexplored molecular changes in 
MDA-MB-231 cells following hepatocyte coculture besides E-cadherin re-expression. 
Immunohistochemistry revealed that besides E-cadherin, expression of gap junction 
molecules connexin 26 (Cx26) and connexin43 (Cx43) were also increased in metastases 
compared to primary tumor. As MDA-MB-231 cells do not normally express these connexins, 
we tested whether re-expression of connexins could also occur. MDA-MB-231 cells cultured 
with human hepatocytes for 6 days revealed punctate localization of Cx43 whereas breast cancer 
cells cultured in the absence of hepatocytes remained Cx43-negative (Figure 17). Lack of a 
human-specific Cx43 antibody prevented the detection of overall protein levels by immunoblot. 
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As we demonstrated that it was possible for mesenchymally-transitioned carcinoma cells 
to revert to a more epithelial phenotype, we next tested whether primary explants of human 
breast tumors could also re-express E-cadherin in hepatocyte coculture. Explants were obtained 
from breast tumors without current evidence of dissemination and cultured for at most 3 passages 
prior to experimentation. In total, four cocultured primary explants were assayed by flow 
cytometry and seven primary explants were analyzed by immunofluorescence following 
hepatocyte coculture.  Analysis by flow cytometry indicated that although initially E-cadherin 
negative, one of the four explants tested expressed E-cadherin after coculture (Figure 18a). 
Similarly, tumor cells in two of seven explants that were originally E-cadherin negative, 
expressed robust and well-localized E-cadherin after 6 days of co-culture with the hepatocytes 
(Figure 18b). We were unable to ascertain the promoter methylation status in these cells due to 
the limited number and passage integrity of the primary cells; nonetheless, this line of evidence 
strongly suggests that primary human breast cancer cells may undergo similar molecular changes 
as MDA-MB-231 cells when cultured in a hepatic microenvironment.  
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Figure 13. MDA-MB-231 cells re-express E-cadherin in hepatocyte coculture A) 
Immunoblot of MDA-MB-231/hepatocyte co-cultures using a human-specific antibody. B) Flow 
cytometry shows a unimodal population on day 0 and a bimodal population on day 6. C) MDA-
MB-231 cells do not express E-cadherin without hepatocytes. D) RT-PCR using human-specific 
primers of MDA-MB-231 cells after 6 days of co-culture with hepatocytes. Means (n=4) ± s.d.  
Note that species-specific primers do not amplify E-cadherin or GAPDH from hepatocytes.  
 
 
A.1.2  
 85 
 
 
Figure 14. Breast cancer cells cultured with hepatocytes revert to an epithelial morphology. 
Phase contrast images of 231, 231-H2kd, 231-Ecad, and 231-shEcad breast cancer cells cultured 
with rat hepatocytes for 6 days. 
 
A.1.2  
 86 
 
 
Figure 15. 231 cells do not revert to an epithelial phenotype in fibroblast coculture. RFP-
labeled 231, 231-Ecad and 231-shEcad cells cultured for 6 days with primary human fibroblasts. 
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Figure 16. Breast cancer cells culture with hepatocytes re-express E-cadherin but maintain 
vimentin Immunostaining of RFP-labeled breast cancer cells in hepatocyte coculture; E-cadherin 
(green), RFP (red), DAPI (blue) and vimentin (green), RFP (red), DAPI (blue).  
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Figure 17. MDA-MB-231 cells re-express connexin 43 after coculture. Immunofluorescence 
of connexin 43 expression in MDA-MB-231 cells with and without hepatocyte coculture. Blue 
(DAPI), green (hepatocyte-specific Hep Par 1), red (connexin43). 
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Figure 18. Primary breast carcinoma explants re-express E-cadherin when cocultured with 
hepatocytes. A) Flow cytometry analysis of primary explants using a human-specific E-cadherin 
antibody. B) Confocal microscopy of two positive explants. Explants (C), hepatocytes (H). 
Human-specific E-cadherin, blue; actin, red; nuclei, green. 
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3.3.3 E-cadherin re-expression in the liver microenvironment is due to loss of promoter 
methylation 
In the absence of hepatocytes, E-cadherin expression in MDA-MB-231 cells is transcriptionally 
repressed by methylation of the E-cadherin promoter. Most intraductal breast carcinomas in 
which E-cadherin is downregulated also exhibit similar promoter hypermethylation (Graff et al., 
1995). Therefore, loss of promoter methylation was examined as a possible mechanism for the 
re-expression of E-cadherin. We assayed a CpG island that was proximal to the E-cadherin 
transcription start site, whose methylation correlates inversely with E-cadherin expression 
(Kallakury et al., 2001). Following coculture, total genomic DNA was isolated for methylation-
specific PCR (MS-PCR) (Corn et al., 2000).  Species-specific primers were used to guarantee 
measurement of CpG methylation in only the human cancer cells and not rat hepatocytes. When 
human MDA-MB-231 cells were co-cultured with rat hepatocytes over a period of 6 days, the 
methylation status of the E-cadherin promoter region changed from a hypermethylated state to a 
hypomethylated state (Figure 19a). However, in the absence of hepatocytes, MDA-MB-231 cells 
remained hypermethylated (Figure 19b).  
Because cancer cells are globally hypomethylated, we evaluated whether the loss of 
methylation was specific to the E-cadherin promoter or the result of global hypomethylation.  
The H19 gene is a paternally imprinted gene whose methylation is modulated during 
gametogenesis and does not change after terminal differentiation of a cell line (Lucifero et al., 
2002). We performed bisulfite MS-PCR analysis on MDA-MB-231 cells before coculture and 
following 1,3, and 6 days of coculture with hepatocytes, examining a previously reported CpG 
site of H19. Evaluation of the data revealed that the average methylation of H19 remained 
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unchanged at all time points indicating that global hypomethylation is not responsible for the 
changes observed at the E-cadherin promoter (Figure 19c). 
Loss of promoter methylation can result from either a passive mechanism (lack of 
maintenance methylation subsequent to mitosis) or an active mechanism (enzyme-mediated 
excision), though there are currently no well-defined demethylases. The presence of intermediate 
stages of promoter methylation on day 3 and extended time period to unmethylated status (6 
days) suggested a passive mechanism. To test whether the loss of methylation was dependent on 
proliferation of the cancer cells, we inhibited proliferation of the cancer cells with mitomycin-C. 
This treatment completely prevented loss of methylation of the promoter as demonstrated by 
MS-PCR (Figure 18d). Furthermore, addition of mitomycin-C also prevented re-expression of E-
cadherin at the protein level (Figure 19e). Inhibition of DNA methyltransferases, which mediate 
CpG island methylation, could also account for loss of methylation. However, immunostaining 
for DNA methyltransferase DNMT1 showed neither decrease in expression nor change in 
nuclear localization (Figure 19f). Taken together, these data point to passive loss of methylation 
as the mechanism by which E-cadherin is re-expressed.  
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Figure 19. Re-expression of E-cadherin follows a proliferation-dependent demethylation of 
the E-cadherin promoter. A) MS-PCR of MDA-MB-231 cultured alone in hepatocyte growth 
media B) MS-PCR using human-specific primers that amplify the imprinted H19 gene. C) MS-
PCR of E-cadherin promoter following addition of MMC D) Addition of MMC prevents E-
cadherin re-expression at the protein level. E) The maintenance demethylase DNMT1 does not 
change in localization or intensity in MDA-MB-231 cancer cells when cocultured with 
hepatocytes.  DNMT1, red; DAPI, blue. 
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3.3.4 E-cadherin re-expression occurs in vivo 
To determine whether reversion of E-cadherin repression could be induced in vivo, we injected 
MDA-MB-231 cells into the mammary fat pads of mice. Mice were sacrificed after four weeks 
to allow for dissemination from the primary tumor. Because MDA-MB-231 cells inoculated into 
the mouse mammary fat pad mainly metastasize to lung and not to liver when allowed to 
spontaneously metastasize, mice were examined for lung metastases. Our use of human breast 
cancer cells in a mouse host allowed for a human-specific E-cadherin antibody to discern the 
source of E-cadherin expression between the cancer cells and the epithelial mouse parenchyma. 
We first confirmed that the primary xenograft transplants in the inguinal mammary fat pads did 
not express E-cadherin (Figure 20a, left panel). There was no change in E-cadherin status of the 
invading cells in the primary xenograft, as we observed both the central and peripheral areas of 
the tumor to be devoid of E-cadherin as detected by immunoperoxidase staining (Figure 20a, 
middle and right panels). Two representative images of lung micrometastases less than 2mm in 
diameter showed a markedly different pattern of E-cadherin expression. When 
immunoperoxidase labeling was performed on these sections, isolated islands expressing E-
cadherin localized to the cell membrane were detected (Figure 20b).  The human-specific 
antibody identified the disseminated MDA-MB-231 cells with robust E-cadherin expression, 
while not labeling the surrounding mouse lung tissue.  Other fields of the same lung, unaffected 
and clear of metastatic lesions, did not display positive staining. Although we were unable to 
obtain metastases to the liver in the animal model, E-cadherin re-expression was observed in 
lung metastases in both the animal model and in clinical samples, suggesting that re-expression 
of E-cadherin may not be limited to the liver microenvironment.  
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Figure 20. E-cadherin positive metastatic foci originate from E-cadherin negative primary 
tumors. A) Left, human MDA-MB-231 breast cancer cell xenograft in a mouse inguinal fat pad 
(H&E); middle, human-specific E-cadherin antibody indicates the absence of E-cadherin 
expression in the primary tumor B) Micrometastases in the lung originating from the primary 
xenograft in A.  Immunoperoxidase labeling of diseased portions of the mouse lung indicate the 
presence of human E-cadherin-positive MDA-MB-231 cancer cells; bottom adjacent. 
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3.4 DISCUSSION 
Paget’s seed and soil hypothesis has long postulated that cancer cells, or the “seeds”, will only 
grow in a specific microenvironment, or “soil” (Fidler, 2003). Indeed, despite the fact that 
tumors are continually shedding cells, very few circulating tumor cells actually establish 
metastases, suggesting that post-extravasation survival is a crucial rate-limiting step (Koop et al., 
1995; Luzzi et al., 1998; Kienast et al., 2010). The clinical observations that breast cancer 
displays a characteristic pattern of metastasis, specifically to the lung, liver, bone, and brain, 
indicate that these organs provide the most conducive microenvironment for metastatic growth. 
In addition, cancer cells themselves may exhibit an inherent gene signature predisposing them to 
homing to a particular organ site (Lu and Kang, 2007). The precise environmental factors that 
enable the organotropism of metastases are yet to be fully discovered, but even less well known 
is why only a tiny fraction of circulating carcinoma cells form metastases. 
Prior to extravasation, cancer cells must survive through invasion and emigration, 
anchorage-independent dissemination, and extravasation into the ectopic organ. These behaviors 
are thought to be conferred by molecular changes as a result of EMT. However, post-
extravasation, cancer cells encounter a new set of challenges, notably integration within organ 
parenchyma and establishment of blood supply, which mesenchymal-like cells appear poorly 
equipped to handle.  Despite the importance of EMT in promoting metastatic progression, there 
is mounting evidence that EMT is not an irreversible switch in cancer cell phenotype. Analysis 
of primary tumors and their corresponding metastases reveal that even though an EMT may have 
occurred to engender metastases, the phenotypes of the two can be strikingly similar (Bukholm 
et al., 2000; Kowalski et al., 2003). Re-expression of adhesion molecules could therefore be one 
way in which the secondary organ microenvironment promotes survival of metastatic cells as 
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cadherin-cadherin ligandation promotes activation of cell survival signaling pathways (Pece and 
Gutkind, 2000). 
Despite our previous findings of increased E-cadherin expression and partial MErT at the 
secondary site, it was possible that these E-cadherin-positive tumor cells disseminated from the 
primary tumor as epithelioid cells and formed secondary metastatic lesions. These results 
corroborate our immunohistochemistry results in breast cancer patient samples, where E-
cadherin expression was observed in metastases but not accompanied by drastic decrease in 
expression of mesenchymal markers. Thus, we sought to provide proof-of-principle that cancer 
cells could be engineered to approach a mesenchymal-to-epithelial reverting transition by 
altering E-cadherin expression, either exogenously or via the microenvironment.  We first 
hypothesized that we could engineer a MErT in MDA-MB-231 cells by expressing wild-type E-
cadherin or by sequestering the E-cadherin-associated catenins with a non-binding E-cadherin 
construct.  After transfecting the MDA-MB-231 cells with the cytosolic domain of E-cadherin 
linked to the MHC external domain, we saw that the dominant negative protein sequestered α-, 
β- and p120- catenins.  The advantage of using this dominant negative is that the catenin 
signaling could be parsed from other activities of the extracellular domain of E-cadherin 
including cell adhesion through trans-ligation and EGFR cis-modulation (Fedor-Chaiken et al., 
2003).  While neither construct could completely revert MDA-MB-231 cells to an epithelial 
phenotype, expression of either construct resulted in morphological transformations and 
behavioral changes noted as suppression of migration and invasion. Our results also corroborate 
the findings of other studies focusing on the role of E-cadherin as a tumor or invasion suppressor 
(Wong and Gumbiner, 2003; Onder et al., 2008; Sarrio et al., 2009). 
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When cultured in a hepatic microenvironment, MDA-MB-231 exhibited a similar 
reversion to an epithelial phenotype, both in morphology and E-cadherin re-expression.  The 
nature of the signals that drive the reversion back to an epithelioid phenotype are not known and 
likely to be complex. Initial studies found that neither conditioned media nor hepatocyte-derived 
matrix could trigger E-cadherin re-expression in this breast carcinoma line, though the 
combination of the two lead to a weak re-expression of E-cadherin (data not shown). These 
results are in line with observations made in patient samples, where E-cadherin expression 
decreased with increasing distance from contact with organ parenchymal cells, suggesting that a 
gradient of soluble factors and contact with parenchymal cells or parenchyma-derived matrix is 
required to maintain E-cadherin expression. Re-expression secondary to loss of methylation of 
the E-cadherin promoter was also observed in the cell line MDA-MB-435 (data not shown), 
which is now considered to be a melanoma derivative, but is nonetheless useful as this 
neurectodermal lineage expresses E-cadherin as melanocytes but loses expression during 
melanoma progression (Silye et al., 1998; Sanders et al., 1999; Rae et al., 2004). Furthermore, 
this reversion is not likely unique to hepatocytes, based on the findings in human metastases and 
in our in vivo mouse model. Recently, we have found that lung parenchymal cells can drive E-
cadherin expression in prostate tumor cells (Li et al., 2010).  Another study suggests that 
laminin-1 may be one component of the extracellular matrix that contributes to E-cadherin re-
expression (Benton et al., 2009). One key difference between our studies is the 
microenvironment used to induce E-cadherin re-expression in MDA-MB-231 cells. While 
Benton et al used a three-dimensional laminin-1 hydrogel, we chose to simulate a secondary 
organ microenvironment by culturing breast cancer cells with hepatocytes, thereby exposing 
them to hepatocyte-derived soluble factors and extracellular matrix. Their finding of DNMT1 
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downregulation as the mechanism for E-cadherin expression was not observed in our system 
(data not shown), suggesting that tissue architecture may induce MErT by alternative 
mechanisms. Thus, the search for this signaling ‘cocktail’ is likely to be complex and lies beyond 
the scope of the present communication. 
Furthermore, probing of mesenchymal marker vimentin reveals that similar to the in vivo 
data, expression of vimentin persists to suggest a partial MErT. Evaluation of epithelial marker 
Cx43 suggested similar re-expression of gap junction molecules, but it is unknown whether the 
gap junctions are functional. Dye transfer studies would need to be performed to determine if re-
expressed Cx43 is functional. Heterotypic formation of gap junctions between breast cancer cells 
and parenchymal cells has been shown previously (el-Sabban and Pauli, 1994; Kanczuga-Koda 
et al., 2007). Not only that, but the ability to form heterotypic gap junctions over homotypic gap 
junctions is increased in metastatic cancer cells compared to non-metastatic cells (Woodward et 
al., 1998). 
That E-cadherin re-expression is caused by loss of methylation suggests a functional 
mechanism by which the microenvironment modulates the mesenchymal to epithelial phenotypic 
switch.  E-cadherin is predominantly downregulated in carcinomas at the post-translational 
and/or transcriptional levels. Regulation of E-cadherin is therefore unique among tumor 
suppressors in which loss or mutation appears to be the rule, but this epigenetic regulation of E-
cadherin allows for increased phenotypic plasticity. We have previously reported that prostate 
cancer cells cultured with hepatocytes also re-express E-cadherin, but as a result of inhibition of 
the EGF receptor signaling (Yates et al., 2007).  However, in breast cancers E-cadherin is 
silenced directly at the transcriptional level by promoter hypermethylation or indirectly through 
its transcriptional suppressors Snail, Slug, and Twist (Graff et al., 1995; Cano et al., 2000; Hajra 
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et al., 2002; Onder et al., 2008). No differences in expression of these transcriptional suppressors 
were observed following hepatocyte coculture (data not shown). In MDA-MB-231 cells, 
representative of the basal subtype of infiltrating ductal carcinomas, the CpG islands in the 
promoter region most proximal to the E-cadherin initiation site are fully methylated, which 
exerts a profound effect on mesenchymal nature. Demethylation of these islands by the chemical 
agent 5-aza-deoxycytidine causes re-expression of E-cadherin and loss of invasive ability (Nam 
et al., 2004). Coculturing of MDA-MB-231 cells with primary hepatocytes resulted in loss of 
methylation of the E-cadherin promoter and expression of E-cadherin mRNA and protein. We 
observed that the loss of methylation was dependent on the proliferation of the cancer cells. This 
finding was not unique to the breast carcinoma cells, as the MDA-MB-435 line also 
demonstrated loss of promoter hypermethylation upon coculturing with hepatocytes. 
Importantly, this loss of methylation was at least semi-specific and not global as the imprinted 
H19 gene remained methylated. The ubiquitous transcription factor Sp1 has been implicated in 
the regulation of methylation status by binding loci of hemimethylated DNA, protecting 
sequences from de novo methylation, preferential demethylation, or passive demethylation 
mechanisms (Holler et al., 1988; Brandeis et al., 1994; Silke et al., 1995; Matsuo et al., 1998). 
Sp1 was necessary for loss of methylation in coculture (data not shown), strongly suggesting 
active signaling from the microenvironment. 
 The foundation of our findings rest on the epigenetic reversion observed when breast 
cancer cells are cocultured with primary hepatocytes. The epigenetic status of the primary tumor 
and disseminated metastases is most likely important, since primary tumors that have high E-
cadherin levels have very little systemic disease (Goldstein, 2002), suggesting that the epigenetic 
reversion at distant secondary sites is also relevant. The xenograft model in which MDA-MB-
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231 cells formed E-cadherin-negative primary tumors in the mammary fat pads but E-cadherin-
positive micrometastases and the finding that primary breast carcinoma explants can re-express 
this molecule support the idea that this reversion is possible. Furthermore, the xenograft 
experiment demonstrates that the molecular changes can occur in the secondary site.  However, 
these experiments do not mean that all E-cadherin-positive metastases necessarily arise from the 
reversion of E-cadherin-negative cancer cells.  Further molecular dissections and a much larger 
breast tumor survey, challenging due to the paucity of matched primary and non-nodal 
metastases, are needed to determine the extent of this MErT in early metastatic seeding.  
The potential implications of E-cadherin re-expression and MErT are many. There are 
several possible outcomes or combinations of outcomes after a cell extravasates into a metastatic 
target tissue: apoptosis, dormancy, or sustained proliferation, with the latter appearing the rarest 
(Chambers et al., 1995; Kienast et al., 2010). While E-cadherin typically mediates homotypic 
cell-cell adhesions, heterophilic ligation between different cell types has been documented 
(Shiraishi et al., 2005). Cancer cell adhesion facilitates extravasation and colonization of distant 
organs (Glinskii et al., 2005; Chu et al., 2008; Gassmann and Haier, 2008). Epithelial phenotypic 
reversion in vivo may therefore enhance the integration and survival of cancer cells at the 
metastatic site by cloaking the cancer cell with epithelial-like characteristics, or may act to 
transmit mitogenic or motogenic signals. E-cadherin expression has been shown to suppress cell 
growth, which may account for the dormancy period between clinical presentation of metastases 
(St Croix et al., 1998; Perrais et al., 2007). However, preliminary results in a parallel study reveal 
that one important survival advantage conferred by E-cadherin expression is increased resistance 
to cell death induced by chemotherapeutic agents such as camptothecin, doxorubicin, and taxol 
(Section 4.0). Cellular adhesion has long been implicated in intrinsic or acquired resistance of 
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solid tumors to multiple anticancer therapeutics not restricted to chemotherapy (St Croix and 
Kerbel, 1997). The addition of E-cadherin function blocking antibodies sensitizes multicellular 
spheroids to treatment with various chemotherapeutic agents and E-cadherin-positive cells are 
more resistant to staurosporine-induced cell death than E-cadherin-negative breast cancer cells 
(Green et al., 2004; Wang et al., 2009). A similar survival advantage may be conferred when 
disseminated cells face apoptotic cytokines, thus providing a selective pressure that then 
confounds adjuvant therapies. The finding that E-cadherin re-expression and catenin 
sequestration can contribute to a MErT suggests that they may be appropriate therapeutic targets 
for preventing the establishment of metastases in breast cancer.  
3.5 MATERIALS AND METHODS 
3.5.1 Generation of cell lines 
231-H2kd cells were generated using the Myc/His encoding H-2kd-E-cad dominant negative E-
cadherin construct, a kind gift from Vizirianakis et al (Vizirianakis et al., 2002). 231-H2kd cells 
were selected by FACS using the H-2kd (SF1-1.1) antibody (BD Pharmingen; San Jose, CA) and 
were maintained in 900μg/ml G418 until used for experimentation. 231-Ecad cells were made by 
co-transfecting a plasmid encoding the E-cadherin full-length cDNA sequence (Origene) with 
the pcDNA 3.1 plasmid (Invitrogen) and cultured in 900μg/ml G418 to select for stable 
transfectants. 231-shEcad cells were generated using an E-cadherin shRNA plasmid (Santa Cruz 
Biotechnology) and stable transfectants were selected using 5ug/ml of puromycin and confirmed 
by RT-PCR. At least two single cell clones of each mutant were generated by selecting for 
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resistance to G418 (231-H2kd and 231-Ecad) or puromycin (231-shEcad). Control clones 
transfected with pcDNA 3.1, DsRed2, and control shRNA were also generated and tested.  
Single cell clones of each mutant line were subsequently transfected with the DsRed2 plasmid 
vector and FACS sorted for RFP fluorescence for use in hepatocyte cocultures. In all cases the 
experiments were performed at least once with the different clones, rendering similar results.  
3.5.2 Cell culture and hepatocyte coculture 
 MCF7, MDA-MB-231, and MDA-MB-435 cells were cultured in RPMI-1640 with 10% FBS as 
previously described (Yates et al., 2007). Primary rat hepatocytes were isolated by collagenase 
perfusion and cultured as described previously and plated onto collagen-coated 6-well plates at 
60,000 cells/cm2. The following day, cancer cells were seeded onto the hepatocyte monolayer at 
3,000 cells/cm2 and cocultured for 6 days. 
3.5.3 Invasion assay 
Invasive potential was determined in vitro by migration through an artificial ECM.  2.5x104 cells 
were challenged in growth-factor reduced matrigel invasion chambers (BD Biosciences).  Cells 
were seeded into the top chamber with serum-free media and media containing 10% serum was 
added to the lower chamber for the remainder of the assay.  After 24 hours, the remaining cells 
and ECM in the top chamber were removed by cotton swab. Cells that invaded through the 
matrix to the bottom of the filter were then fixed and stained with DAPI and counted.  Individual 
experiments were performed in triplicate.  
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3.5.4 Migration assay 
A monolayer of cells was grown to confluence in a 6-well plate and at experimental time zero a 
scratch was made in each well using a pipette tip.  The well was imaged at time zero and again 
24 hours later.  Using Metamorph, a measurement was taken for how much the denuded area had 
filled in the 24-hour period. 
3.5.5 Xenografts 
The Institutional Animal Care and Use Committee at the Veterans Affairs Hospital in Pittsburgh 
approved all animal procedures. Experiments were performed in 8-week-old female athymic 
nude mice. One million MDA-MB-231 cells were injected into the right mammary fat pad; 
injection vehicle was the culture medium (0.2 mL/site). Mice were sacrificed 4-5 weeks after 
tumor cell implantation and the primary xenograft and lungs removed. 
Xenograft and other harvested tissues were fixed in 4% buffered formalin and 4μm thick 
paraffin sections underwent antigen retrieval for 5 min in 95°C 10mM citrate solution in 
preparation for H&E and immunochemistry. With the use of the Mouse on Mouse Kit (Vector 
Labs, Berlingame, CA), positive labeling was confirmed by comparing serial sections incubated 
with the primary human-specific E-cadherin antibody (67A4 1:100; Santa Cruz Biotechnology, 
Santa Cruz, CA) or the biotinylated secondary antibody alone. Labeling was visualized with the 
Vectastain Elite kit (Vector Labs). 
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3.5.6 Methylation specific PCR and bisulfite sequencing 
DNA was isolated from co-culture using the DNeasy Blood and Tissue Kit (Qiagen, Velencia, 
CA). 2000ng of isolated DNA was subjected to bisulfite treatment using the EZ DNA 
Methylation Gold Kit (Zymo, San Diego, CA) per the manufacturer’s specifications. MSP was 
performed in the way of Corn (Corn et al., 2000) or using the CpG WIZ E-cadherin 
Amplification Kit per the manufacturer’s instructions (Millipore, Temecula, CA).  Briefly, in the 
method of Corn, a nested PCR method was used, in which the first primer set generated a 270bp 
fragment that was subsequently sequenced.  The second round of PCR used either nested primers 
that were specific to either the unmethylated or methylated allele, which amplified the first CpG 
island after the transcription start site.  The product size of the methylated reaction was 112bp 
and 120bp for the unmethylated. 
  MSP of H19 after bisulfite conversion was performed using the following primers: F 5’-
TTA TAA AAT CGA AAA TTA CGC GCG A-3’ R 5’-TTT TAG ATG ATT TTT GTG AAT 
TTT-3’. Cycling conditions were 95 °C for 15 min, 35 cycles of 94°C for 1 min, 55°C for 1 min, 
and 72°C for 1 min with a final extension of 5 min at 72 °C. All reactions were performed using 
Platinum Taq SuperMix (Invitrogen). 
3.5.7 Real-time quantitative PCR 
RNA was isolated from hepatocyte-cancer cell co-cultures with the PureYield RNA Midiprep 
System (Promega, Madison, WI). cDNA was obtained with High Capacity cDNA RT Kit 
(Applied BioSystems, Foster City, CA). The human-specific TaqMan Gene Expression Assay 
Hs00170423_A1 CDHI probe was obtained from Applied Biosystems (Foster City, CA). 
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Amplification and analysis in quadruplicate was run in an Applied Biosystems 7500 Real-Time 
PCR System. Relative values were normalized by using GAPDH levels as a reference using 
TaqMan Pre-Developed Human GAPDH Assay Reagent by Applied Biosystems. 
3.5.8 Immunoblotting, Immunofluorescence, and Flow Cytometry 
Cell lysate proteins were resolved on 7.5% SDS-PAGE and transferred to PVDF membranes. 
After blocking, membranes were incubated with primary antibodies against E-cadherin (Santa 
Cruz), pan cytokeratin (abcam), smooth muscle actin (Cal Biochem), fibronectin (Rockland Inc), 
GAPDH (Sigma) and actin (Sigma), followed by incubation with peroxidase-conjugated 
secondary antibodies and chemiluminescence detection. 
For flow cytometry, co-cultures were non-enzymatically dissociated from the culture 
plates and vortexed into a single-cell suspension. The cells were fixed in 2% Paraformaldehyde 
for 30 minutes, permeabilized with 1% Triton for 3 minutes, and incubated with a PE-conjugated 
E-cadherin antibody (67A4) for 30 minutes. The mixed hepatocyte-cancer cell suspension was 
gated as to exclude hepatocytes using the appropriate SSC/FSC parameters. Data were collected 
on at least 106 cells in the appropriate SSC/FSC region.  
Immunofluorescence was performed by overnight primary antibody incubation with E-
cadherin (Santa Cruz), DNMT1 (Santa Cruz), DsRed (Santa Cruz), Alexa 488-phalloidin 
(Molecular Probes), cytokeratin-18 (abcam) or vimentin (abcam) followed by incubation with 
the appropriate fluorophore-labeled secondary antibody. Visualization was performed on an 
Olympus Fluoview 1000 confocal microscope (Olympus, Center Valley, PA). 
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3.5.9 Primary explants 
Polyclonal primary human tumor explants were obtained and cultured as previously reported 
(Ochs et al., 2003).  Immunofluorescence labeling was performed as above. 
3.5.10 Statistical analyses 
All quantitative data are presented as mean ± sd obtained from independent experiments.  p-
value significance was determined using a two-tailed unpaired Student t-test, and set at 0.05 as a 
minimum.  All images were representative of at least three independent observations. 
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4.1 ABSTRACT 
Metastatic colonization is a rate-limiting step of metastasis. Metastatic nodules are often 
refractory to current therapies, making necessary the elucidation of molecular changes that 
enable cancer cell survival and chemoresistance at the secondary site. Drug resistance exhibited 
by tumor spheroids is mediated by cell adhesion and can be abrogated with addition of E-
cadherin blocking antibody. Indeed, exogenous expression of E-cadherin in MDA-MB-231 cells 
increased resistance to cell death induced by chemotherapy and nutrient deprivation. Similar 
results were obtained in DU-145 prostate cancer cells chemically induced to re-express E-
cadherin by buserelin or PD153035. We have previously shown that MDA-MB-231 breast 
cancer cells can be induced to re-express E-cadherin in a partial mesenchymal to epithelial 
reverting transition (MErT) when co-cultured with hepatocytes. E-cadherin re-expression in 
breast cancer cells facilitated heterotypic adhesion to hepatocytes, activated Erk survival 
signaling, and decreased LC3 localization to autophagosomes, suggesting a functional pro-
survival role for E-cadherin during metastatic colonization of the liver. In addition, MDA-MB-
231 cells that re-expressed E-cadherin in hepatocyte coculture were more chemoresistant 
compared to cells stably transfected with E-cadherin shRNA. This effect was further amplified 
when MDA-MB-231 cells were cultured in 3D in a liver bioreactor, which more closely 
approximates the liver microenvironment. These results reveal that in the liver 
microenvironment, breast cancer cells undergo molecular changes not just limited to E-cadherin 
re-expression that confer a survival advantage and may help to elucidate why chemotherapy 
commonly fails to treat metastatic breast cancer.   
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4.2 INTRODUCTION 
About 30% of breast cancer patients will present with distant, non-nodal metastases, and as high 
as 60-70% of those patients will develop metastases in the liver (Viadana et al., 1973; Lermite et 
al., 2010). Breast cancer that metastasizes to the liver carries a very poor prognosis, with the 
median survival at around 24 months (Atalay et al., 2003). Only 5% of patients with liver 
metastases present with a singular nodule, and as a result surgical resection is not an option for 
most. Current treatment for liver metastases relies on a multi-modal approach of systemic 
chemotherapy, endocrine- or HER2-targeted therapy if dictated by ER/PR/HER2 status, and 
palliative therapy such as radiation (Diamond et al., 2009).  Poor response to chemotherapy is a 
major reason for the high mortality for breast cancer patients with liver metastases, and for all 
metastatic cancer patients in general. Therefore elucidating the mechanisms behind 
chemoresistance in metastasis is valuable for developing more effective therapies. 
Just as not much is known about why metastases are refractory to chemotherapy, little is 
known about the molecular mechanisms controlling the colonization of breast cancer in the liver. 
Breast cancer exhibits organotropism, meaning it preferentially localizes to bone, liver, lung and 
brain, despite circulating through many other organs (Viadana et al., 1973). Lumen occlusion 
alone is insufficient for liver colonization (Gassmann et al., 2009). Selective cellular adhesion  
accounts for some of the organotropism exhibited by cancers, as cancer cell line variants that 
exhibit increased liver metastasis potential show increased adhesion to embryonic mouse liver 
cells (McGuire et al., 1984). Similarly, loss of claudins is associated with EMT while the 
upregulation of other tight junction components occurs in liver metastases. In vivo selection for a 
liver-aggressive variant of 4T1 breast cancer cells reveals that claudin-2 is upregulated in liver 
metastases and improves adhesion of the liver-aggressive cells to fibronectin and collagen IV, 
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key components of the liver ECM (Tabaries et al., 2010). Selectins are a family of cell adhesion 
molecules that are differentially expressed on the vascular endothelial cells of various organs; 
colon cancer cells express different selectin ligands to adhere to particular organs (Mannori et al., 
1995; Paschos et al., 2009). Expression of cell adhesion molecule E-cadherin on breast cancer 
cells may be another mechanism to facilitate adhesion to hepatocytes, the E-cadherin expressing 
parenchymal cells that account for 70-80% of the liver.  
Besides mediating physical adhesion to organ parenchymal cells to facilitate 
colonization, expression of E-cadherin is also associated with cell survival. Although lacking 
intrinsic kinase activity, E-cadherin can contribute to cell signaling through transactivation of 
EGFR. Expression of E-cadherin on hepatocyte spheroids in culture protects against detachment-
induced cell death, or anoikis, in a caspase-independent manner (Luebke-Wheeler et al., 2009). 
Similarly, endocytosis of E-cadherin induced by EGFR activation leads to anoikis of enterocytes 
(Lugo-Martinez et al., 2009). The assembly of adherens junctions coordinated by E-cadherin 
ligation leads to rapid activation of MAPK and Akt, signaling pathways critical for cell survival 
(Pece et al., 1999; Pece and Gutkind, 2000). VE-cadherin also controls endothelial cell survival 
through signaling through Akt and Bcl-2 (Carmeliet et al., 1999). Thus, breast cancer cells may 
activate survival signaling through heterotypic ligation with hepatocytes.  
We have shown previously that E-cadherin expression and partial MErT are observed in 
human breast cancer metastases. We have also shown that E-cadherin is re-expressed in the liver 
microenvironment by culturing breast cancer cells with hepatocytes in vitro. Thus this study aims 
to determine whether there is a functional significance to E-cadherin re-expression. We show 
that E-cadherin can promote attachment to the secondary organ through heterotypic ligation, 
resulting in the activation of survival signaling. Furthermore, E-cadherin re-expression also 
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confers a survival advantage by increasing the resistance of breast cancer cells to chemotherapy 
and nutrient deprivation-induced cell death in the liver microenvironment. 
4.3 RESULTS 
4.3.1 E-cadherin expression affects survival through heterotypic adhesion of breast 
cancer cells to hepatocytes 
We have previously shown that E-cadherin-negative MDA-MB-231 cells re-express E-cadherin 
and revert to an epithelial morphology when cultured with hepatocytes (Chao et al., 2010). As 
mediating intercellular adhesion is a major function of E-cadherin, we hypothesized that post-
extravasation survival of cancer cells at the secondary site could be facilitated by heterotypic 
adhesion between cancer cells and organ parenchymal cells. To test whether attachment to 
hepatocytes was dependent on E-cadherin expression we used previously characterized E-
cadherin knock-in and knock-out mutants: E-cadherin-negative MDA-MB-231 cells, MDA-MB-
231 cells that exogenously express E-cadherin (231-Ecad), MDA-MB-231 cells stably 
expressing E-cadherin shRNA (231-shEcad), E-cadherin-positive MCF7 cells, and MCF7 cells 
stably expressing E-cadherin shRNA (MCF7-shEcad). All cell lines were RFP-labeled to 
facilitate detection of cancer cells in hepatocyte coculture. Primary rat or human hepatocytes 
were plated on collagen-coated plates at 30% confluency and 2x104 cancer cells were seeded 
onto the monolayer the following day. 24 hours later, the number of RFP-positive cells in the 
monolayer was counted as a measure of attachment. The E-cadherin-positive 231-Ecad and 
MCF7 cell lines exhibited twice the number of adherent cancer cells compared to E-cadherin-
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negative cell lines (Figure 21a). However, it was possible that the differences in attachment were 
not entirely E-cadherin dependent, as the plating of hepatocytes at 30% confluency left portions 
of the collagen-coated plastic exposed. As a result, the cell lines were plated on differing 
hepatocyte densities ranging from 25 to 100% confluency. Thus, at higher hepatocyte densities 
attachment could only be generated by cancer cell adhesion to the hepatocyte monolayer. As 
expected, the ability of E-cadherin-positive 231-Ecad and MCF7 cells to attach was not affected 
by hepatocyte density while attachment of E-cadherin-negative 231 and MCF7-shEcad cells 
decreased with increasing hepatocyte density (Figures 21b and 21c). While lack of E-cadherin 
expression initially impeded the ability of 231 cells to attach to hepatocytes, re-expression of E-
cadherin following 6 days of hepatocyte coculture increased attachment, as measured by a 
centrifugal assay for fluorescence-based cell adhesion (data not shown).  
E-cadherin ligation activates survival signaling pathways (Pece et al., 1999; Pece and 
Gutkind, 2000) so we queried whether heterotypic ligation between breast cancer cells and 
hepatocytes resulted in similar activation. To expose signaling only occurring in the breast 
cancer cells, hepatocyte membranes were isolated and adsorbed onto culture plates. Activation of 
the Erk pathway was probed after MDA-MB-231 cells isolated from cocultures were plated onto 
hepatocyte membranes. Maximal Erk activation was observed 30 minutes after addition of E-
cadherin re-expressing 231 cells, which was similar to signaling observed following addition of 
E-cadherin expressing MCF7 cells (Figure 22). Erk activation was not detected when 231 cells 
cultured in the absence of hepatocytes, and therefore remained E-cadherin-negative, were plated 
onto hepatocyte membranes. 
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Figure 21. E-cadherin expression increases attachment to hepatocytes. A) Attachment of E-
cadherin -negative and –positive breast cancer cells to hepatocyte plated at 30% confluency, 24 
hours after plating B and C) Attachment of E-cadherin –negative and –positive breast cancer 
cells to hepatocytes plated at 25 to 100% confluency, 24 hours after plating.  
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Figure 22. Hepatocyte coculture activates Erk survival pathways in breast cancer cells. Erk 
phosphorylation was measured at various time points following plating of breast cancer cells 
onto hepatocyte membranes. A) MCF7 cells B) 231 cells with and without hepatocyte coculture  
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4.3.2 E-cadherin expression increases resistance to starvation  
As the secondary organ microenvironment may be considerably different compared to the 
primary tumor microenvironment in terms of growth factor and nutrient milieu, we next tested 
whether E-cadherin expression affected the cancer cell response to starvation. To determine 
whether E-cadherin expression affected the ability of cancer cells to respond to starvation, we 
cultured our cell lines in growth media or serum-free media for 3 days and counted the number 
of surviving cells daily. By the end of the starvation period, there were more surviving cells in E-
cadherin-positive cell lines (Figure 23a). There is increasing evidence that cancer cells exploit 
starvation by employing autophagy to catabolically degrade intracellular components for 
nutrients. We therefore stained nutrient deprived breast cancer cells and breast cancer cells 
cocultured with hepatocytes for autophagy marker LC3. When 231 cells were cultured in serum-
free media, immunostaining revealed LC3 localized to autophagosomes. Autophagosomes were 
not observed in 231 cells cultured with hepatocytes, suggesting either a reduction in autophagy 
upon E-cadherin re-expression or an increase in nutrients produced by hepatocytes (Figure 23b).  
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Figure 23. E-cadherin expression increases survival under starvation. A) E-cadherin –
negative and –positive cells cultured in with (RPMI) and without serum (HGM) for 3 days. B) 
LC3 immunofluorescence of 231-RFP cells cultured with and without hepatocytes. Green (LC3), 
Red (RFP-labeled 231 cells) 
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4.3.3 E-cadherin re-expression increases chemoresistance 
Multiple studies have shown that E-cadherin protects against cell death and increases drug 
resistance (St Croix and Kerbel, 1997; Green et al., 2004; Wang et al., 2009). Treatment of the 
breast cancer cells with the protein kinase inhibitor staurosporine and chemotherapeutic drug 
camptothecin showed that 231-Ecad cells were less sensitive to cell death induced by these 
agents compared to E-cadherin negative 231 and 231-shEcad cells (Figures 24a and 24c). 
Addition of E-cadherin antibody abrogated the effect on 231-Ecad cells (data not shown). 
Furthermore, E-cadherin re-expression in hepatocyte coculture increased the chemoresistance of 
231 cells to 231-Ecad levels, while 231-shEcad cells remained the most sensitive (Figures 24b 
and 24d). Interestingly, overall the breast cancer cells were less chemosenstive in hepatocyte 
coculture as the IC50 was 10 fold higher in coculture, which may be explained by molecular 
changes besides E-cadherin re-expression that allow for a more complete reversion to the 
epithelial phenotype not observed when only E-cadherin is exogenously expressed.  
We corroborated these results in prostate cancer cells as we have previously shown that 
prostate cancer cells re-express E-cadherin upon repression of EGFR signaling (Yates et al., 
2005; Yates et al., 2007). DU-145 prostate cancer cells were treated with 1ug/ml of buserelin, 
luteinising hormone-releasing hormone (LHRH) analog or 500nM EGFR kinase inhibitor 
PD153035 for 48hrs. Treatment with these agents resulted in re-expression of E-cadherin and an 
epithelial cluster morphology (Figures 25a and 25b). Following E-cadherin re-expression 
induced by these agents, DU-145 cells were more resistant to cell death induced by staurosporine 
and camptothecin (Figure 25c). The small degree of protection can be explained by the fact that 
not all of the prostate cancer cells re-express E-cadherin under the treatment. 
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Figure 24. E-cadherin re-expression in hepatocyte coculture increases chemoresistance. A 
and C) Staurosporine- and camptothecin-induced cell death in breast cancer cells without 
hepatocytes B) Staurosporine- and camptothecin-induced cell death in breast cancer cells after 6 
days of coculture with hepatocytes  
B 
C D 
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Figure 25. E-cadherin re-expression in prostate cancer cells increases chemoresistance. A) 
Immunoblot for E-cadherin following treatment with buserelin or PD153035. B) 
Immunofluorescence for E-cadherin following treatment C) DU-145 cells treated with 
camptothecin and staurosporine with or without re-expression of E-cadherin by buserelin and 
PD153035.  
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4.3.4 E-cadherin re-expression in a organotypic liver bioreactor increases 
chemoresistance 
The microenvironments of both the orthotopic and metastatic sites undoubtedly play a crucial 
role in tumor progression. In addition, significant experimental differences have been shown 
between 2D and 3D culture, with 3D culture able to recapitulate a more accurate 
microenvironment. We therefore used an organotypic bioreactor to more closely recapitulate the 
liver microenvironment, as fluid flow dynamics of circulation through hepatic sinusoids is 
captured in this system (Figure 27a).  Liver toxicity studies performed in this particular 
bioreactor shows that hepatocytes cultured in this manner more closely resemble the gene, 
protein, and metabolic expression profiles of hepatocytes in vivo (Sivaraman et al., 2005). 
Hepatocytes were seeded in collagen-coated scaffolds in the bioreactor and allowed to organize 
into spheroids for 48 hours. RFP-labeled MDA-MB-231 cells were then seeded onto bioreactor 
scaffolds to incorporate within the hepatocyte spheroids. Following 10 days of culture, spheroids 
were gently detached from scaffolds and imaged. Both 231 and 231-Ecad cells exhibited a 
cluster morphology within spheroids, while 231-shEcad cells remained diffuse throughout 
spheroids, suggesting that the 231 cells had reverted to a morphology similar to the 231-Ecad 
cells. scaffolds were removed and fixed and stained for E-cadherin (Figure 26). Scaffolds were 
also fixed with spheroids still attached within the channels for immunostaining, which revealed 
E-cadherin-positive cells on RFP-labeled 231 cells within scaffold channels (Figure 27b). After 
10 days of culture, different doses of staurosporine were added to the media and allowed to 
circulate for 24 hours. The next day scaffolds were removed intact from the bioreactor and 
placed into the wells of a 12-well plate. RFP fluorescence was measured using a microplate 
reader. While 231 and 231-shEcad cells exhibited similar drug response curves prior to 
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hepatocyte coculture, preliminary results show that the response to staurosporine greatly 
diverged following E-cadherin re-expression in 231 cells in the liver bioreactor (Figure 27c). 
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Figure 26. 231 cells revert to an epithelial morphology following 3D culture in a liver 
bioreactor.  
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Figure 27. E-cadherin re-expression in 3D bioreactor culture increases chemoresistance A) 
Image of multi-well perfused bioreactor B) Immunofluorescence of E-cadherin expression after 
10 days of culture in bioreactor, blue (DAPI), red (RFP), green (E-cadherin), yellow (RPP and E-
cadherin merge). 
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4.4 DISCUSSION 
Alterations in adhesion have been shown to be necessary for many steps of metastasis, from 
down-regulation of E-cadherin in EMT during invasion to expression of selectin ligands or gap 
junction molecules for adherence to endothelial cells during extravasation (McGuire et al., 
1984). We have shown previously that metastatic tumors from breast cancer patients express 
increased levels of E-cadherin compared to the primary tumor, which is accompanied by a partial 
mesenchymal to epithelial revert transition. Furthermore, E-cadherin re-expression is also 
observed when cultured in a liver microenvironment in vitro and in lung metastases in an in vivo 
animal model (Chao et al., 2010). Our findings herein show that the functional significance of E-
cadherin expression in metastases may be to increase attachment and integration within organ 
parenchyma, and to subsequently increase post-extravasation survival through E-cadherin-
mediated survival signaling. Besides physical intercellular adhesion, E-cadherin engagement also 
activates internal signaling pathways that promote survival through suppression of anoikis and 
canonical Erk and Akt pathways (Pece et al., 1999; Pece and Gutkind, 2000). E-cadherin binding 
of renal epithelial cells indeed promotes survival in a PI-3K–dependent fashion (Bergin et al., 
2000). The finding that Erk is phosphorylated upon binding to hepatocytes by re-expressed E-
cadherin on MDA-MB-231 cells implies relevant functional signaling occurs as a result of 
heterotypic ligation.  
What remains is the question of whether E-cadherin expression is required for the 
establishment of metastases. E-cadherin re-expression could explain the propensity for breast 
cancer cells to metastasize to lung and liver, both lined with epithelia. Aberrant expression of 
osteoblast cadherin, also known as OB-cadherin and cadherin-11, on breast and prostate cancer 
cells, increases metastases to the bone by increasing migration and intercalation with osteoblasts 
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(Chu et al., 2008; Li et al., 2008). Tsuji et al, approached this question by showing that EMT-
induced cells transfected with E-cadherin failed to form metastases (Tsuji et al., 2009). However, 
it is possible that their method of EMT induction by overexpressing p12 interfered with reversion 
of the epithelial phenotype. An experimental model of metastasis through intrasplenic injection 
of 231, 231-Ecad, and 231-shEcad would answer the question of whether E-cadherin expression 
is necessary for metastatic colonization. It is likely that while not necessary, there is an 
advantage to expression of expression of adhesion molecules such as E-cadherin. 
We have shown herein that one such advantage is the increased resistance to nutrient 
deprivation and chemotherapy-induced cell death. Previous studies have shown the protective 
role of E-cadherin in the face of chemotherapy and our studies of chemoresistance in breast and 
prostate cancer cells alone corroborate these results (St Croix and Kerbel, 1997). Another way in 
which E-cadherin expression can increase the survival of cancer cells is through autophagy. 
During tumorigenesis, mutations in the autophagic pathway can promote tumorigenesis; however 
once the cancer is established, activation of autophagy can help cancer cells to survive nutrient 
deprivation as they encounter different microenvironments (Karantza-Wadsworth and White, 
2007; Kenific et al., 2009). However, autophagy only protects against short-term starvation; as 
prolonged nutrient deprivation still leads to cell death.  E-cadherin expressing cells are more 
protected against starvation, and although we were unable to show a difference in LC3 protein 
expression we did observe a difference in localization to autophagosomes. The finding that there 
is decreased autophagy in hepatocyte cocultures suggests that the microenvironment is nutrient-
sufficient. Treatment with autophagy inducer rapamycin in hepatocyte cocultures may reveal 
additional protective role of E-cadherin re-expression.   
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Of particular interest is the finding that breast cancer cells in hepatocyte coculture, both 
in 2D and 3D, were more resistant to cell death-induced by staurosporine or camptothecin 
compared to cells cultured in the absence of hepatocytes. While E-cadherin re-expression 
increased the chemoresistance of 231 cells compared to 231-shEcad cells, even in hepatocyte 
coculture 231-shEcad cells were more resistant compared to 231-shEcad cells cultured alone. We 
have shown that in human samples and in hepatocyte coculture a partial mesenchymal to 
epithelial reversion occurs, suggesting that the liver microenvironment can induce other 
molecular changes besides E-cadherin expression during partial MErT (Chao et al., 2010). One 
such change can be re-expression of the gap junction protein connexins, which are frequently 
downregulated in EMT and have been shown to be upregulated in lymph node metastases. 
Additionally, hepatocyte coculture induces re-expression of connexin43 in breast cancer cells. 
As we showed previously, brain metastases of breast cancer patients exhibit increased expression 
of E-cadherin, Cx43 and Cx 26. A recent study showed that astrocyte-cancer cell interactions 
mediated by gap junction expression protects cancer cells from chemotherapy-induced cell death 
(Langley et al., 2009; Lin et al., 2010). Thus adhesion, facilitated by gap junctions in this case, 
promotes the survival of cancer cells during metastatic colonization.  
The mechanisms behind the increased chemoresistance in E-cadherin re-expressing cells  
in our model is still unknown. Posible mechanisms behind the chemoresistance include 
upregulation of anti-apoptotic proteins such as Bcl-2 or cell cycle inhibitors cyclin-dependent 
kinase inhibitor p27 (St Croix et al., 1996; Wang et al., 2009). Activation of Akt also contributes 
to chemoresistance (West et al., 2002). Another potential explanation for the increased 
chemoresistance is contact mediated growth inhibition governed by E-cadherin (St Croix et al., 
1998). However, growth inhibition of MDA-MB-231 cells upon re-expression of E-cadherin was 
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not observed in hepatocyte coculture (data not shown). Furthermore, there are several therapeutic 
implications raised by this study. Our previous results suggest that anti-adhesive therapy may not 
be the best method of overcoming E-cadherin-mediated chemoresistance, as disrupting E-
cadherin cell adhesions would induce EMT in the metastatic tumor. The survival signals 
activated upon heterotypic E-cadherin ligation or the as yet unknown microenvironmental cues 
that initially induce expression of E-cadherin in the secondary organ may thus be the more 
effective therapeutic targets.    
4.5 MATERIAL AND METHODS 
4.5.1 Cell lines and cell culture 
231-RFP, 231-Ecad-RFP, and 231-shEcad-RFP breast cancer cells and DU-145 prostate cancer 
cells were cultured as previously described (Chao et al., 2010). For autophagy studies, cells were 
cultured in serum-free RPMI or HGM for 3 days. 
4.5.2 Coculture 
Primary rat and human hepatocytes were isolated and plated on 6-well plates coated with 10% 
rat tail collagen in dH2O (BD Biosciences) at 30% confluency and allowed to attach overnight. 
The next day, 2x104 RFP-labeled cancer cells were seeded onto hepatocyte monolayers. Rat 
cocultures were maintained in Hepatocyte Growth Media (HGM) and human hepatocytes were 
maintained with Hepatocyte Maintenance Media (Lonza). Media was replenished daily.  
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4.5.3 Chemical re-expression of E-cadherin  
DU-145 cells were seeded in 96-well plates and treated with 1ug/ml buserelin or 500nM 
PD153035 for 48hrs. Immunoblot and immunofluorescence to confirm E-cadherin expression 
was performed using E-cadherin antibody (Cell Signaling). 
4.5.4 Attachment assay 
Primary hepatocytes were plated at densities ranging from 25-100% confluency on collagen-
coated 6-well plates and allowed to attach overnight. The next day, 2E4 RFP-labeled cancer cells 
were seeded in each well. 24 hours later, wells were washed once with PBS to remove any 
unattached cells and the number of RFP+ cells in each well was quantified.  
4.5.5 Chemoprotection assay 
For cell death assays in the absence of hepatocytes, breast and prostate cancer cells were seeded 
in 96-well plates and treated with 0 to 1000nM of staurosporine for 24 hours or 0 to 100µM of 
camptothecin for 48 hours. Wells were then stained with 1uM calcein AM for 30 minutes and 
fluorescence was quantified with Tecan Spectrafluor. In the presence of hepatocytes, following 
induction of cell death with staurosporine or camptothecin, the number of RFP+ cells in each 
well was counted.  
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4.5.6 Hepatocyte membrane assay 
Culture plates were coated with poly-L-lysine (Sigma) and hepatocyte membranes (2 mg 
protein/cm2) were allowed to adsorb onto poly-L-lysine-coated 6-well plates for 10 minutes. 
Hepatocyte membranes were labeled with DiI (Molecular Probes) for visualization. MDA-MB-
231 cells were sorted from hepatocyte cocultures and quiesced in serum-free media for 3 hours, 
then seeded 2E4 cells onto the membrane coated plates and centrifuged at 50g for 1 minute.  
RIPA lysates were taken at each time point and pErk (Santa Cruz Biotech) was detected by 
immunoblot.  
4.5.7 Bioreactor 
A three-dimensional multiwell perfused liver bioreactor based on one previously described by 
Yates et al was used (Yates et al., 2007). 769-channeled polycarbonate scaffolds were coated 
with 30µg/ml collagen I and placed into reactor wells. 800,000 hepatocytes primary rat or human 
hepatocytes in single-cell suspension were seeded into scaffold channels and allowed to attach 
and reorganize for 48 hours. 20,000 RFP-labeled breast cancer cells were then seeded onto 
scaffolds and allowed to expand within the hepatocyte microtissue for 10 days. Media was 
changed every other day. For immunofluorescence to confirm E-cadherin expression, scaffolds 
were removed and fixed in 4% paraformaldehyde for 1 hour and permeabilized in 0.1% Triton-X 
for 30 minutes. Primary antibody incubation with E-cadherin (Cell Signaling) and DsRed2 
(Santa Cruz) was performed overnight and 1 hour secondary antibody incubation (Alexafluor-
488 and -594) at room temperature. Tissue structures within scaffold channels were visualized 
using an Olympus Fluoview 1000 confocal microscope (Olympus, Center Valley, PA). For the 
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cell death assay, reactor wells were treated with 0 to 1000nM staurosporine on day 10. The next 
day scaffolds were removed and placed in PBS in the well of a 12-well plate. RFP fluorescence 
was analyzed using a Tecan SpectraFluor. 
 
 
 
 
A.1.2  
 131 
5.0  DISCUSSION 
While the library of studies investigating cancer-associated epithelial to mesenchymal transition 
is rapidly expanding, the field of mesenchymal to epithelial transition in cancer is still nascent. 
We have provided in vivo evidence of differential expression of epithelial and mesenchymal 
markers in primary and metastatic tumors, suggesting that MErT is possible at the secondary site. 
We have shown increased expression of epithelial markers at the metastatic site compared to the 
primary tumor; however this change is accompanied by persistence of mesenchymal markers 
suggesting a partial MErT. Furthermore, we demonstrated organ-specific expression of adhesion 
molecules in the form of connexin expression in brain metastases, which may contribute to 
organotropism to the brain. Using an in vitro coculture of liver parenchymal cells with breast 
cancer cells, we also provide evidence that this increased epithelial expression observed in 
metastases can be due to reversion of the mesenchymal phenotype rather than expansion of 
epithelial cells from the primary tumor. Both the mechanism of E-cadherin regulation, 
methylation of the promoter, and persistence of mesenchymal markers facilitate the switching 
between different phenotypes. Finally, we have demonstrated that this E-cadherin expressed on 
different cell types, cancer cells and hepatocytes, can mediate heterotypic ligation that increases 
cancer cell attachment to the target organ. This ligation improves survival through activation of 
canonical signaling pathways and increased resistance to chemotherapy. In short, we have shown 
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that the liver microenvironment is able to induce a part mesenchymal to epithelial reverting 
transition to confer a survival advantage to metastatic breast cancer cells in the liver.  
5.1 FUTURE DIRECTIONS 
5.1.1 Signals driving MErT 
The signals from the microenvironment that cause E-cadherin re-expression are still unidentified. 
Previous work in the lab suggests that a combination of soluble factors secreted by hepatocytes 
and hepatocyte-derived matrix is required for E-cadherin re-expression (data not shown). These 
results are also supported by the finding that a gradient of E-cadherin expression can be observed 
in patient samples, with highest expression in areas in closest contact with organ parenchymal 
cells (Chao et al., 2010). One potential avenue of future research is thus the explication of these 
signals. Laminin-1 may be one such critical ECM component, as 3D culture of MDA-MB-231 
cells in a laminin gel induces loss of methylation of the E-cadherin promoter and re-expression 
(Benton et al., 2009). 2D culture of MDA-MB-231 cells in hepatocyte-conditioned media on 
different ECM-coated surfaces has not uncovered other ECM components involved; however, 
3D culture of ECM components may be more revealing. Similarly, a deductive method of 
applying blocking antibodies to conditioned media or the use of an antibody-array may 
illuminate the soluble factors involved. Whether or not physical contact between hepatocytes and 
E-cadherin is necessary for re-expression is undetermined.   
Also unknown is whether an active signal to induce MErT is required, or if only a 
removal of EMT-inducing stimuli is necessary. Preliminary experiments suggest that there is no 
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correlation between protein expression of EMT master regulators Snail, Slug, and Twist and E-
cadherin expression in our system (data not shown). However, cellular localization of these 
proteins was not investigated. Mesenchymal to epithelial transition in development is well-
studied in terms of kidney morphogenesis; therefore parallels in these processes may give some 
insight into signals that drive MErT. FGFs are necessary for epithelialization of nephric 
mesenchyme during kidney development (Urban et al., 2006). In a model of lung fibrosis, an 
example of fibrosis-associated EMT in which alveolar epithelial cells convert to 
fibroblasts/myofibroblasts, TGF-β induced EMT can be reverted by addition of FGF-1 and 
heparin in combination or HGF alone (Shukla et al., 2009; Ramos et al., 2010). Similarly, 
expression of hepatocyte nuclear factor 4 alpha (HNFα) in fibroblasts induces mesenchymal to 
epithelial transition (Parviz et al., 2003; Kanazawa et al., 2010). HNF4α is a dominant driver of 
the epithelial phenotype in the liver as conditional knockout during hepatogenesis results in 
disorganized tissue architecture of hepatocytes that do not express E-cadherin nor form cell-cell 
contacts (Parviz et al., 2003). Further analysis reveals that HNF4a is responsible for expression 
of all cell junction genes, including adherens, tight, and gap junctions (Battle et al., 2006), 
suggesting that HNF4a is a key orchestrator of epithelial phenotype in the liver. As we have 
shown that E-cadherin re-expression increases the survival of cancer cells in the liver 
microenvironment, elucidating the signals that induce MErT may be critical to developing 
therapies to target metastatic colonization. 
5.1.2 Organotypic bioreactor as an experimental tool for studying metastasis 
The chemoresistance of breast cancer cells was seemingly amplified when cultured in 3D in the 
organotypic bioreactor compared to when cultured in 2D on collagen-coated plastic. This finding 
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suggests that the bioreactor may thus be a more useful experimental tool that more closely 
approximates how cells behave in vivo. Similarly, studies in 3D are a more accurate reflection of 
how cells will respond to drugs and other therapeutics than in 2D cell culture. An added benefit 
of the bioreactor is that it allows for relatively high throughput testing of drugs. One of the major 
drawbacks to studies of EMT and MErT is that the transient dynamism of plasticity is difficult to 
capture using static techniques such as immunostaining or even gene expression profiling. 
Models like the bioreactor can combine 3D culture with real-time imaging of metastatic 
progression. The involvement of other cells in the liver microenvironment, such as endothelial, 
stellate, or Kupffer cells can also be elucidated by introduction into the bioreactor.  
5.2 EPITHELIAL PLASTICITY IN CANCER 
Epithelial to mesenchymal transition has captured great interest over the years as a 
developmental program that is re-articulated in pathological processes such as metastasis and 
fibrosis. However, there is a movement toward using terms such as “epithelial mesenchymal 
plasticity” instead of EMT to denote a difference between these reversible, and often partial or 
intermediate phenotypic switches, and the irreversible conversion to a mesenchymal phenotype 
observed in developmental EMT. Processes such as endothelial to mesenchymal transition 
(EndoMT) and epithelial to myofibroblast transition (EMyT) denoting similar phenotypic 
switches have also been defined (Kizu et al., 2009; Masszi et al., 2010). At the core of these 
phenotypic transitions is the idea that differentiated cells are much more plastic than originally 
thought, as also underlined by studies involving induced pluripotent stem cells and metaplasia. 
Most importantly, through epigenetic regulation that can be induced by the microenvironment, 
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EMT and MErT allow cancer cells to easily switch between motile and immotile, adhesive and 
non-adhesive, proliferative and non-cycling states; these adaptations can all occur without the 
acquisition of genetic mutations.  
5.2.1 The hunt for a master regulator 
Many independent inducers of EMT have been discovered and hundreds of genes are 
differentially expressed between epithelial and mesenchymal phenotypes, initiating a search for a 
master regulator. It is becoming more evident that there is a hierarchy of regulation, with Snail 
and Twist at the top (Foubert et al., 2010). Besides these transcriptional regulators, microRNAs 
(miRNAs) are a family of non-coding RNAs that inhibit translation by binding target mRNAs. 
MicroRNAs are often dysregulated in cancer, which can consequently induce EMT (Valastyan et 
al., 2009; Tryndyak et al., 2010). Intriguingly, the miR-200 family of microRNAs is involved in 
a reciprocal repressive feedback loop with ZEB, a transcriptional repressor of E-cadherin and 
EMT inducer (Burk et al., 2008; Brabletz and Brabletz, 2010). In EMT, the balance shifts in 
favor of ZEB, which is also a transcriptional repressor of miR-200. In MErT, expression of miR-
200 increases to inhibit translation of ZEB, which is then unable to repress transcription of E-
cadherin, therefore pushing cells toward an epithelial phenotype. The signature of EMT-
associated gene expression is also driven by master programs of chromatin organization, DNA 
methylation, and splicing (Han et al., 2008; Warzecha et al., 2010). 
Recent evidence suggests that induction of EMT in cancer cells confers stem cell 
properties, providing a link between EMT and the cancer stem cell hypothesis. Ectopic 
expression of Snail or Twist not only results in induction of EMT as expected, but cells also 
acquire expression of stem cell markers CD44high/CD24low with increased ability to form 
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mammospheres. Similarly, stem-like cells isolated in vivo express EMT markers (Mani et al., 
2008; Morel et al., 2008). In breast cancer cell lines, there is a significant overlap in expression 
of genes in the EMT signature and mammary stem cell signature (Blick et al., 2010). 
5.2.2 MErT in metastatic colonization 
Many studies have shown that inducing EMT in the primary tumor can increase metastases, and 
in these studies EMT is usually irreversibly induced, suggesting that reversion at the secondary 
site is not necessary for establishment. However, use of the 4T1 cell line and its variants, which 
were derived from a single, spontaneously generated tumor, have provided some insight into the 
role of E-cadherin in colonization (Aslakson and Miller, 1992). The cell lines 67NR, 168FARN, 
4T07, and 4T1 can all form primary tumor when injected orthotopically, but vary in the ability to 
form metastases, with 4T1 cells able to form macroscopic tumors in lung, liver, bone, and brain, 
and 67NR cells unable to intravasate and subsequently form metastases. 168FARN cells form 
only lymph node metastases and 4TO7 cells disseminate to lung but do not form macroscopic 
lung metastases. Interestingly, not only is E-cadherin only expressed in 4T1 cells, but there is 
also dramatic up-regulation of the miR-200 family of miRNAs, which repress translation of E-
cadherin transcription repressor ZEB2. Expression of vimentin is equal among all the cell lines, 
indicating some persistence of mesenchymal phenotype (Lou et al., 2008; Dykxhoorn et al., 
2009). Repression of ZEB and increased expression of E-cadherin in 4TO7 cells increases 
invasion and the ability to form macroscopic nodules. However, these studies only directly tested 
the roles of ZEB and miR-200, and not E-cadherin, in metastatic colonization, as both ZEB and 
miR-200 have many downstream targets besides E-cadherin. 
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5.2.3 A model for EMT and MErT in cancer 
Based on the literature and our findings we present a model for the role of EMT and MErT in 
metastatic progression (Figure 28). Although rarely captured in patient samples, in vivo imaging 
and in vitro studies have conclusively provided evidence that EMT contributes to metastatic 
dissemination. However, EMT is not the only mechanism of invasion nor is it absolutely 
required. EMT results in loss of E-cadherin expression and disruption of intercellular adhesion, 
disturbing the compartmentalized and polarized architecture of epithelia and resulting in 
autocrine growth factor activation and increased interactions with stroma cells and matrix.  As a 
consequence of EMT, cancer cells slide toward a mesenchymal phenotype and gain motility and 
the ability to process and degrade the ECM en route to dissemination. Following survival in the 
circulation and extravasation, adhesion to the secondary organ is mediated by re-expression of E-
cadherin and other adhesion molecules in a partial MErT. This model of a more differentiated 
phenotype at the metastatic site also supports the hypothesis that the cells that exhibit the EMT 
phenotype are stem-like. Post-extravasation survival, one of the rate-limiting steps of metastasis, 
is thus facilitated by heterotypic ligation between cancer cells and parenchymal cells. Following 
proliferation of cancer cells in the ectopic organ and angiogenesis that generates a 
macrometastasis, the exposure of cancer cells to microenvironmental signals decreases and new 
cycles of EMT can occur to generate metastases from metastases.   
Where dormancy fits into this chronology is a question that should be explored further. 
Studies have shown that EMT involves a switch from a proliferative to a lower-cycling, 
migratory state, suggesting that after MErT cancer cells would become proliferative (Kent et al., 
2009). However, the role of E-cadherin in contact-dependent growth inhibition is well-
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established, so it is unclear whether a period of dormancy would precede or succeed re-
expression of E-cadherin.  
 Importantly, MErT is not a process that is limited to breast cancer and metastases to the 
liver. We have previously shown that prostate cancer cells cocultured with hepatocytes also re-
express E-cadherin, although the mechanism of re-expression is through inhibition of EGFR 
signaling (Yates et al., 2007). Prostate cancer is the most common malignancy in men and 
exhibits a specific pattern of metastases similar to breast cancer: bone, lung, and liver 
(Bubendorf et al., 2000). Other similarities between breast and prostate cancer include 
dependency on hormones, roles of the stroma in tumor progression, and EMT as a mechanism 
for metastatic initiation (Henshall et al., 2001; Hugo et al., 2007; Risbridger et al., 2010). The 
prostate also relies on the underlying mesenchyme during development (Cunha, 2008). In our 
studies, immunohistochemistry of prostate cancer primary and metastatic tumors revealed 
increased E-cadherin expression as observed in breast cancer metastases. Cell death assays of 
prostate cancer cells chemically induced to re-express E-cadherin through EGFR inhibition 
suggest that the function of E-cadherin re-expression in prostate cancer may be similar. 
 Our results suggest that MErT is not limited to liver metastases but may be extrapolated 
to colonization of other organs as well. Tail vein injection of MDA-MB-231 cells in mice 
resulted in E-cadherin-positive foci in the lung. These results were supported by 
immunohistochemistry of human lung metastases as well as in vitro coculture of breast cancer 
cells and pneumocytes (Li et al., 2010). Breast cancer metastases to bone and brain also express 
E-cadherin, so it remains to be seen whether E-cadherin expression facilitates attachment to these 
organs where the parenchymal cells do not express E-cadherin. Although E-cadherin expression 
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is observed in brain metastases, it may be other adhesions such as gap junctions that coordinate 
the survival and chemoresistance of cancer cells in the brain.  
 
 
 
Figure 28. Model for EMT and MErT in metastatic progression 
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5.3 THERAPEUTIC IMPLICATIONS 
Mortality of breast cancer is largely attributed to chemoresistance of metastases. The findings 
presented herein unfortunately do not reveal a clear therapeutic target; rather, the phenotypic 
plasticity of cancer complicates development of therapeutic interventions. When EMT was first 
described, induction of E-cadherin expression in the primary tumor was touted as a way to 
prevent invasion and metastasis. Given our results, such therapies may have the unwanted side 
effect of promoting secondary metastases. Conversely, anti-adhesive antibodies to prevent re-
expression of E-cadherin and other adhesion molecules at the metastatic site are burdened with 
the possibility of inducing EMT and causing dissemination of metastases from metastases, a 
possibility supported by our in vivo analysis of E-cadherin expression correlated with metastatic 
tumor size. However, even if EMT is induced, anti-adhesive therapy may prevent attachment and 
colonization, resulting in circulating tumor cells without the formation of metastases, much like 
the 4TO7 cell line described earlier. An additional problem is that targeting one adhesive 
molecule may not be sufficient, as others can compensate. Strategies of targeting the so-called 
“master regulators” of EMT/MErT such as transcriptional repressors and microRNAs may be 
more effective at enacting multi-level molecular changes. 
Similarly, our results that show increased chemoresistance in breast cancer cells 
following E-cadherin re-expression are complicated by the fact that many studies have also 
shown that cells that have undergone EMT are more resistant to chemotherapy and radiotherapy. 
One such example is in non-small cell lunng cancer where the E-cadherin-positive cohort is more 
susceptible to treatment with EGFR inhibitor erlotinib compared to E-cadherin-negative tumors 
(Buck et al., 2007). Whether there are differences in the mechanisms behind resistance in EMT 
and the resistance in MErT is unknown.  The key to overcoming the problem of cancer cell 
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plasticity is probably multi-modal therapy to target multiple cell populations concurrently. 
Screens have identified several agents that selectively kill cancer stem cells/EMT cells (Gupta et 
al., 2009). Such agents may be more effective when used in combination with an agent to target 
cells that have already gone MErT, such as blocking the signals from the secondary 
microenvironment that induce E-cadherin re-expression.  
Studies have independently evaluated the prognostic value of both EMT markers and 
EMT gene signatures; however, clinical implementation of evaluating EMT and MErT status is 
limited. The main constraints are temporal and spatial heterogeneity in expression and the lack of 
good phenotypic markers of EMT/MErT. The plasticity of cancer cells implies that the 
phenotype of the cell is constantly in flux, and as we have shown cells exist in intermediate states 
where both epithelial and mesenchymal markers are present. As a result, temporal and spatial 
heterogeneity means that phenotypic status can differ depending on the time course of cancer 
progression and even within the same tumor. Furthermore, as we have discussed in Section 2.4 
there are no good markers to identify breast cancer cells that have undergone EMT and now 
exhibit a more mesenchymal phenotype. For example, circulating tumor cell assays isolate CTCs 
based on epithelial marker EpCAM, leaving out the population of circulating cancer cells that 
have gone through EMT and lost expression of EpCAM.  
 
 
 
 
 
 
 
 
 
A.1.2  
 142 
5.4 CONCLUSION 
Our finding that E-cadherin re-expression and partial mesenchymal to epithelial reverting 
transition may have an important role in metastatic colonization has seemingly unleashed more 
questions than answers. However, the phenotypic plasticity exhibited by cancer cells throughout 
metastatic progression likely explains why singular therapies have limited success in the clinic. 
Hopefully this work will lead toward a combinatorial approach that is both targeted to tumor 
cells and the microenvironment, thus limiting these phenotypic transitions at multiple stages of 
progression. 
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ABBREVIATIONS 
5FU – 5-fluorouracil 
ABC – ATP-binding cassette transporter 
CAF – cancer-associated fibroblast 
CAFCA – centrifugal assay for fluorescence-based cell adhesion 
CK – cytokeratin 
CMV - cytomegalovirus 
CSF-1 – colony stimulating factor 
CTC – circulating tumor cells 
Cx26 – connexin 26 
Cx43 – connexin 43 
CXCR – C-X-C receptor 
DCIS – ductal carcinoma in situ 
DNMT – DNA methyltransferase 
E-cadherin – Epithelial cadherin 
ECM – extracellular matrix  
EGF – epidermal growth factor 
EGFR – epidermal growth factor receptor 
EMT – epithelial to mesenchymal transition 
ER – estrogen receptor 
EpCAM – epithelial cell adhesion molecule 
FACS – fluorescence-activated cell sorting 
FAK – focal adhesion kinase 
FGF – fibroblast growth factor 
FSC – forward scatter  
FSP1 – fibroblast specific protein 
GFP – green fluorescent protein 
HGF – hepatocyte growth factor 
HGM – hepatocyte growth media 
HNF – hepatocyte nuclear factor 
HPC – hematopoietic progenitor cell 
HUVEC – human vascular endothelial cell  
ICAM – intercellular adhesion molecule 
IDC – infiltrating ductal carcinoma 
IL – interleukin 
ILC – invasive lobular carcinoma 
IGF – insulin growth factor  
LHRH – luteinising hormone-releasing hormone 
MErT – mesenchymal to epithelial reverting transition 
MMC – mitomycin C 
MMP – matrix metalloprotease 
MSC – mammary stem cell 
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MS-PCR – methylation specific polymerase chain reaction 
N-cadherin – Neural cadherin 
N-CAM – neural cell adhesion molecule 
NPC – non-parenchymal cell 
PDGF – platelet-derived growth factor 
PR – progesterone receptor 
PTHrP – parathyroid hormone-related protein 
RFP – red fluorescent protein 
SBRT – stereotactic body radiotherapy 
SDF - stromal cell-derived factor 
SIRT – selective internal radiotherapy 
SSC – side scatter  
TACE – transarterial chemoembolization 
TAM – tumor associated macrophages 
TGF – transforming growth factor  
TNF – tumor necrosis factor  
VCAM – vascular cell adhesion molecule 
VE-cadherin – vascular endothelial cadherin 
VEGF – vascular endothelial growth factor 
XIAP - X-linked inhibitor of apoptosis protein 
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